All conditions

Epilepsy

Plain English clinical trial information, updated daily from ClinicalTrials.gov and public government registries. Not medical advice.

2021
Trials on record
314
Recruiting now
13
Australian sites
30
Phase 3 trials
20
PBS medicines
How these figures are counted
  • Trials on record is every trial tagged to this condition at any stage, except those withdrawn before starting or terminated early. Most are completed rather than ongoing, so this is a measure of research history, not of current activity. It is also smaller than the sitewide "trials tracked" figure, which does include withdrawn and terminated trials.
  • Recruiting now counts only trials whose registry status is "Recruiting". Trials listed as not yet recruiting or enrolling by invitation are excluded, so this understates how many may open to new participants soon.
  • Australian sites counts trials counted under "Recruiting now" that list at least one Australian site. A site being listed does not mean it is currently enrolling, and Australian trials registered only on ANZCTR are not counted yet, so this understates local availability.
  • Phase 3 trials counts trials counted under "Recruiting now" that are at Phase 3.

Find recruiting trials for Epilepsy →

Get alerts when Epilepsy trials change ↗

Voxsanity currently covers 103 conditions. We are expanding coverage regularly.

Understanding Epilepsy

Epilepsy is a condition that affects the brain, causing a person to have repeated seizures. A seizure happens when there is a sudden burst of unusual electrical activity in the brain, which can briefly change how a person moves, thinks, feels, or behaves. Seizures can look very different from person to person. Some people shake or lose consciousness, while others might simply stare blankly for a few seconds or experience a strange feeling or smell. Epilepsy is not a single condition but rather a broad term that covers many different types, each with their own patterns and causes.

Epilepsy is one of the most common neurological conditions in Australia, affecting around 250,000 people across all ages, backgrounds, and walks of life. It can begin at any age, though it is most often diagnosed in young children and in older adults. In many cases, doctors cannot find a specific cause, while in others, epilepsy may be linked to things like a brain injury, a stroke, an infection, or genetics. Being diagnosed with epilepsy can feel overwhelming, but it is important to know that many people with the condition live full and active lives.

Treatment for epilepsy generally focuses on reducing or stopping seizures. The most common approach is medication, and there are many different types available. Because epilepsy varies so much between individuals, finding the right medication or combination can take some time. For some people whose seizures are not controlled by medication, other options such as surgery, dietary therapies, or medical devices that stimulate the brain may be considered. A specialist neurologist will work with the person to understand their specific type of epilepsy and discuss what options may be suitable for their situation.

This overview is an AI generated summary written from public medical sources and checked on a sample basis. It is general information, not medical advice or a diagnosis. Always speak with your doctor about your situation. How we use AI

Can you access treatment for Epilepsy in Australia right now? Here's what's publicly known.

Information on this site does not constitute medical advice. Data is sourced from publicly available government registries. Always consult your doctor before making any health decisions. Trial status should be verified directly with the trial site.

Updated regularly from public government registries

PBS-subsidised medicines for Epilepsy

20 medicines listed on the PBS for Epilepsy. Filter by authority type, or open the full table below.

What the authority types mean Unrestricted: no clinical criteria; a doctor can prescribe it on the PBS for any appropriate use. Restricted benefit: subsidised only for the specific conditions or uses set out by the PBS. Streamlined authority: restricted, but the doctor does not need prior approval; they record a streamlined authority code confirming you meet the criteria. Authority required: restricted, and the doctor must get prior approval from Services Australia (by phone or online) before it is subsidised. Source: Pharmaceutical Benefits Scheme (pbs.gov.au).
Full PBS medicines table 20 listed

These medicines are listed on the Pharmaceutical Benefits Scheme (PBS) for the specific indications shown. A listing does not mean a medicine is right for you; your doctor decides what is appropriate. Prices shown are the PBS-determined dispensed price. Most patients pay only the standard co-payment, up to AU$25.00 per script (general) or AU$7.70 (concession or Safety Net) in 2026, with the Australian Government subsidising the rest.

Medicine Brand(s) Listed for
Gabapentin Neurontin Focal onset seizures AU$3.76 Streamlined authority
Tiagabine Gabitril Focal onset seizures AU$22.73 Streamlined authority
Vigabatrin Sabril Focal onset seizures AU$44.41 Streamlined authority
Zonisamide Zonegran Focal onset seizures AU$10.41 Streamlined authority
Brivaracetam Briviact Intractable focal onset seizures AU$131.83 Streamlined authority
Lacosamide Lacosamide ARX, Vimpat, Lacosamide Sandoz +1 more Intractable focal onset seizures AU$5.7 Streamlined authority
Perampanel Fycompa Intractable focal onset seizures AU$15.52 Streamlined authority
Cannabidiol Epidyolex myoclonic epilepsy in infancy (Dravet syndrome) Severe AU$1400 Authority required
Fenfluramine Fintepla myoclonic epilepsy in infancy (Dravet syndrome) Severe AU$4474.84 Authority required
Stiripentol Diacomit myoclonic epilepsy in infancy (Dravet syndrome) Severe AU$293 Streamlined authority
Clonazepam Rivotril, Paxam 0.5, Paxam 2 Epilepsy AU$3.15 Authority required
Phenobarbital Phenobarbital Tablets, USP 30 mg (Rising Pharmaceuticals, USA), Phenobarb, Phenobarbitone Injection (Aspen Pharmacare Australia Pty Ltd) Epilepsy AU$5.2 Restricted benefit
Lamotrigine Lamictal Epileptic seizures AU$4 Restricted benefit
Levetiracetam Levactam, Levetiracetam-AFT Epileptic seizures AU$7.18 Restricted benefit
Lacosamide Lacosamide ARX, Vimpat, Lacosamide Sandoz +1 more Idiopathic generalised epilepsy with primary generalised tonic-clonic seizures AU$5.7 Streamlined authority
Perampanel Fycompa Idiopathic generalised epilepsy with primary generalised tonic-clonic seizures AU$15.52 Streamlined authority
Oxcarbazepine Trileptal Seizures AU$40.2 Streamlined authority
Topiramate APO-Topiramate, Topamax Sprinkle Seizures AU$4 Streamlined authority
medium chain triglycerides MCT Oil, Liquigen Intractable childhood epilepsy AU$17.95 Streamlined authority
Nitrazepam Alodorm Myoclonic epilepsy AU$2.5 Authority required
amino acid formula with vitamins and minerals without lysine and low in tryptophan GA explore5 Pyridoxine dependent epilepsy AU$210.33 Restricted benefit
Everolimus Afinitor Refractory seizures associated with tuberous sclerosis complex AU$318.6 Authority required
Cannabidiol Epidyolex Seizures of the Lennox-Gastaut syndrome AU$1400 Streamlined authority

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.

Research pipeline

Where trials for Epilepsy currently sit in the development pipeline. The funnel shape shows how few drugs reach later phases in general; the counts are this condition's actual trial numbers.

Phase success rates are industry-wide historical averages, not predictions for specific trials. Learn how trials work →

Most active research sponsors

Organisations with the most recruiting trials for Epilepsy.

View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile

Where trials are running

Clinical trial sites for Epilepsy by country. Australia is highlighted.

Showing the top 10 of 56 countries with trial sites.

Clinical trials for Epilepsy

Showing 325 of 325 trials

The plain English eligibility text on each trial below is an AI generated summary of the official criteria, checked on a sample basis. How we use AI

🇦🇺 NCT00520741 · UCB BIOSCIENCES, Inc. Phase 3 · 13 countries Completed
Completed Phase 3 Est. completion 1 December 2012
🇦🇺 AU🇦🇹 AT🇨🇦 CA🇩🇰 DK🇫🇷 FR🇩🇪 DE🇮🇪 IE🇮🇹 IT +5 more

Who might be able to join this trial: - You have been diagnosed with epilepsy involving partial seizures (either simple partial seizures with physical movement, or complex partial seizures, with or without spreading to a full seizure) - You have between 2 and 40 seizures within any 28-day period - You are taking a stea...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02408549 · UCB BIOSCIENCES, Inc. Phase 3 · 21 countries Completed
Completed Phase 3 Est. completion 30 March 2023
🇦🇺 AU🇧🇷 BR🇧🇬 BG🇨🇳 CN🇨🇿 CZ🇫🇷 FR🇩🇪 DE🇭🇺 HU +13 more

**Who might be able to join this trial:** - You must have either completed the related parent study (NCT02408523) or have been a certain type of participant who did not meet that study's requirements from the start ("Baseline failure"). - In some cases, people who were screened for the parent study but did not fully pa...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02682927 · Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc. Phase 3 · 11 countries Completed
Completed Phase 3 Est. completion 29 July 2020
🇦🇺 AU🇧🇪 BE🇨🇦 CA🇩🇰 DK🇫🇷 FR🇩🇪 DE🇮🇹 IT🇯🇵 JP +3 more

**Who might be able to join this trial:** - Children and teenagers between 2 and 18 years old (male or female, but not pregnant or breastfeeding females) - Has been diagnosed with Dravet syndrome, where seizures are not fully controlled by current seizure medications - Has had a minimum number of convulsive (shaking/j...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT03355209 · Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc. Phase 3 · 14 countries Completed
Completed Phase 3 Est. completion 23 May 2024
🇦🇺 AU🇧🇪 BE🇨🇦 CA🇩🇰 DK🇫🇷 FR🇩🇪 DE🇮🇹 IT🇯🇵 JP +6 more

**Who might be able to join this trial:** - You are male, or female and not pregnant or breastfeeding, and are between 2 and 35 years old (inclusive) at the time of the screening visit. - You have been clinically diagnosed with Lennox-Gastaut syndrome, and seizures that cause you to fall or drop are not fully controlle...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT03572933 · Marinus Pharmaceuticals Phase 3 · 8 countries Completed
Completed Phase 3 Est. completion 31 July 2020
🇦🇺 AU🇫🇷 FR🇮🇱 IL🇮🇹 IT🇵🇱 PL🇷🇺 RU🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - You have a confirmed genetic mutation in the CDKL5 gene, started having seizures before age 1, and were not able to walk independently by age 2 - Seizures have not been well controlled even after trying 2 or more anti-seizure medications - You have at least 16 seizures of the...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT03650452 · Takeda Phase 2 · 8 countries Completed
Completed Phase 2 Est. completion 9 June 2020
🇦🇺 AU🇨🇦 CA🇨🇳 CN🇮🇱 IL🇵🇱 PL🇵🇹 PT🇪🇸 ES🇺🇸 US

**Who might be able to join this trial:** - Children and teenagers between 2 and 17 years old (both boys and girls) - Have been diagnosed with Dravet Syndrome (DS) or Lennox-Gastaut Syndrome (LGS) - Weigh at least 10 kilograms (about 22 pounds) at the screening appointment - Are currently taking between 1 and 4 seizure...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT04938427 · Takeda Phase 3 · 18 countries Completed
Completed Phase 3 Est. completion 25 January 2024
🇦🇺 AU🇧🇪 BE🇨🇦 CA🇨🇳 CN🇫🇷 FR🇩🇪 DE🇬🇷 GR🇭🇺 HU +10 more

**Who might be able to join this trial:** - You (or your child) have been formally diagnosed with Lennox-Gastaut Syndrome (LGS). - You (or your child) have had at least 8 "drop" seizures (sudden falls or collapses caused by seizures) per month for the 3 months before the screening visit, and this continues during a 4–...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT04940624 · Takeda Phase 3 · 18 countries Completed
Completed Phase 3 Est. completion 11 April 2024
🇦🇺 AU🇧🇷 BR🇨🇦 CA🇨🇳 CN🇫🇷 FR🇩🇪 DE🇬🇷 GR🇭🇺 HU +10 more

**Who might be able to join this trial:** - You or your child has been formally diagnosed with Dravet Syndrome (DS). - There have been 12 or more convulsive (tonic-clonic or other major) seizures in the 12 weeks before the screening visit, and at least 4 convulsive seizures per 28 days during a 4- to 6-week observatio...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT05219617 · SK Life Science, Inc. Phase 3 · 16 countries Recruiting
Recruiting Phase 3 Est. completion 1 February 2027
🇦🇷 AR🇦🇺 AU🇨🇴 CO🇩🇪 DE🇬🇷 GR🇭🇺 HU🇮🇱 IL🇮🇹 IT +8 more

**Who might be able to join this trial:** - People who have a documented diagnosis of Lennox-Gastaut syndrome (LGS), confirmed by having more than one type of seizure (including at least one drop or stiffening seizure), a specific brainwave test (EEG) result showing patterns consistent with LGS, and a history of devel...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT05419492 · Encoded Therapeutics Phase 2 · 3 countries Recruiting
Recruiting Phase 2 Est. completion 1 January 2028
🇦🇺 AU🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - Children aged 6 months to under 36 months (for Part 1A), 48 months to under 18 years (for Part 1B), or 6 months to under 48 months (for Part 2), depending on which part of the trial is relevant - People who have a specific type of change (called a predicted loss of function...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT05518578 · Supernus Pharmaceuticals, Inc. Phase 2 · 2 countries Recruiting
Recruiting Phase 2 Est. completion 31 December 2027
🇦🇺 AU🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with treatment-resistant epilepsy, as confirmed by a specialist epilepsy review group called the Epilepsy Study Consortium. - People aged 18 to 70 years old at the time of screening. - People who are able to read, understand, and sign a consent...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT05667142 · Xenon Pharmaceuticals Inc. Phase 3 · 20 countries Recruiting
Recruiting Phase 3 Est. completion 1 April 2027
🇦🇷 AR🇦🇺 AU🇦🇹 AT🇧🇪 BE🇧🇬 BG🇨🇦 CA🇨🇱 CL🇭🇷 HR +12 more

**Who might be able to join this trial:** - People aged 12 or older with a body mass index (BMI) of 40 or below at the first visit - People who have tried at least 2 anti-seizure medicines at proper doses without becoming seizure-free - People who have had a specific type of seizure called primary generalised tonic-cl...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT05716100 · Xenon Pharmaceuticals Inc. Phase 3 · 20 countries Recruiting
Recruiting Phase 3 Est. completion 1 October 2026
🇦🇷 AR🇦🇺 AU🇦🇹 AT🇧🇪 BE🇧🇬 BG🇨🇱 CL🇭🇷 HR🇨🇿 CZ +12 more

**Who might be able to join this trial:** - You are willing to sign a written consent form after being fully informed about the study and its risks - You have been diagnosed with focal epilepsy (a type of epilepsy that starts in one specific area of the brain) for at least 2 years, and have already tried at least 2 sei...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT05947656 · Genovate-NaviFUS (Australia) Pty Ltd. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2026
🇦🇺 AU

**Who might be able to join this trial:** - You have been diagnosed with temporal lobe epilepsy (a type of epilepsy starting in the temporal lobe of the brain) that has not been controlled by medication. - You have had at least 4 seizures over a 60-day observation period, with each seizure happening on a different day...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
🇦🇺 NCT06401538 · Bright Minds Biosciences Pty Ltd Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 15 September 2025
🇦🇺 AU

**Who might be able to join this trial:** - People who have been diagnosed with Absence Epilepsy (with or without eyelid myoclonia, also called Jeavons Syndrome), or a type of severe epilepsy known as Developmental and Epileptic Encephalopathy (DEE), such as Dravet syndrome, Lennox-Gastaut syndrome, or another form of...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06660394 · Longboard Pharmaceuticals Phase 3 · 16 countries Recruiting
Recruiting Phase 3 Est. completion 21 August 2026
🇦🇺 AU🇧🇪 BE🇧🇷 BR🇨🇦 CA🇨🇳 CN🇫🇷 FR🇩🇪 DE🇮🇹 IT +8 more

Who might be able to join this trial: - The person has been diagnosed with Dravet Syndrome (DS), with seizures that first started between 1 and 20 months of age. - The person has a history of at least one of these seizure types: prolonged generalized tonic-clonic, hemiclonic, myoclonic, tonic, atonic, atypical absence,...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06908356 · Praxis Precision Medicines Phase 2 · 3 countries Recruiting
Recruiting Phase 2 Est. completion 1 July 2025
🇦🇺 AU🇪🇸 ES🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with focal onset seizures (seizures that start in one part of the brain) or a type of generalized seizure called idiopathic generalized tonic-clonic seizures (full-body convulsive seizures with no known structural cause). - You have had a brain scan (...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07010471 · Praxis Precision Medicines Phase 3 · 3 countries Recruiting
Recruiting Phase 3 Est. completion 1 December 2026
🇦🇺 AU🇧🇷 BR🇺🇸 US

**Who might be able to join this trial:** - You have been officially diagnosed with a developmental and epileptic encephalopathy (a brain condition that causes both developmental challenges and seizures). - Your seizures first started before the age of 12. - You weigh more than 7 kg (about 15.4 lbs) at the time of sign...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07156201 · Actio Biosciences, Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 March 2026
🇦🇺 AU

Who might be able to join this trial: - People between 18 and 55 years of age (inclusive) - People with a body mass index (a measure of body weight relative to height) between 18 and 32 - People who are generally in good health, with no significant medical concerns found during health checks, blood tests, urine tests,...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07238868 · Shanghai Zhimeng Biopharma, Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2029
🇦🇺 AU

**Who might be able to join this trial:** - People who have read and understood what the study involves, including its risks, and have agreed to take part by signing a consent form before the study begins. - People who completed the full earlier study (CB03-154-EP201) without leaving early, met all the rules of that s...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07640191 · iVEAcare Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2027
🇦🇺 AU

**Who might be able to join this trial:** - People aged 4 to 75 years. - People who have focal (partial) seizures or generalised seizures that have not been controlled by anti-seizure medications. - People who have had at least 4 seizures per month on average over the 90 days before enrolling. - People diagnosed with D...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
🇦🇺 NCT00692003 · Eisai Limited Phase 3 · 13 countries Terminated
Terminated Phase 3 Est. completion 1 November 2008
🇦🇺 AU🇭🇷 HR🇨🇿 CZ🇪🇪 EE🇫🇮 FI🇩🇪 DE🇭🇺 HU🇱🇹 LT +5 more

**Who might be able to join this trial:** - You are male or female and between 6 and 65 years old. - You have had at least 3 major generalized seizures (where the whole body is involved) in the two months before the study starts, with at least one seizure in each of those months. - Your seizures are caused by a type o...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT00693017 · Eisai Limited Phase 3 · 13 countries Terminated
Terminated Phase 3 Est. completion 1 November 2008
🇦🇺 AU🇭🇷 HR🇨🇿 CZ🇪🇪 EE🇫🇮 FI🇩🇪 DE🇭🇺 HU🇱🇹 LT +5 more

**Who might be able to join this trial:** - You are male or female and between 12 and 65 years old - You have had at least 8 days with myoclonic seizures (sudden, brief muscle jerks) over a 2-month period, as part of a type of epilepsy called Idiopathic Generalised Epilepsy (IGE) - You (or your parent/caregiver if you...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT01390220 · UCB Biopharma S.P.R.L. Phase 3 · 11 countries Terminated
Terminated Phase 3 Est. completion 1 March 2017
🇦🇺 AU🇨🇦 CA🇩🇪 DE🇭🇺 HU🇮🇱 IL🇮🇹 IT🇳🇿 NZ🇵🇱 PL +3 more

**Who might be able to join this trial:** - You have a responsible adult caregiver who can watch for and recognize your seizure episodes - You have been diagnosed with epilepsy (either partial or generalized) with a confirmed pattern of seizure clusters - Your seizure clusters last at least 10 minutes - Your seizure cl...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT00041600 · Harvard University Faculty of Medicine Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2030
🇺🇸 US

Who might be able to join this trial: - People of any age, whether male or female. - People who have a brain malformation, a family history of intellectual disability, or a diagnosis of autism. Who may not be able to join: - People who do not have a brain malformation, intellectual disability, or autism. Important: A...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT00060541 · National Institute of Neurological Disorders and Stroke (NINDS) Not Applicable · 1 country Recruiting
Recruiting Not Applicable
🇺🇸 US

**Who might be able to join this trial:** - You must be 4 years of age or older - You must be seeking care from, or be referred to, the Surgical Neurology Branch for a brain or nervous system condition — such as brain tumors, nerve tumors, epilepsy, Parkinson's disease, movement disorders, Chiari syndrome, nervous syst...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT01238250 · Simons Searchlight Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2050
🇺🇸 US

Who might be able to join this trial: - People of any age who have a genetic condition included on the trial's eligible conditions list, as well as their biological family members (the current list of eligible conditions can be found at the trial's official website). - People who are fluent in English, Spanish, French,...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT01273129 · National Institute of Neurological Disorders and Stroke (NINDS) Not Applicable · 1 country Recruiting
Recruiting Not Applicable
🇺🇸 US

Who might be able to join this trial: - People aged 8 years or older who have epilepsy that has not responded well to medication, or epilepsy related to a brain tumor. Who may not be able to join: - People who are unable or unwilling to give their own informed consent to take part in the research, or, for those under...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT01662453 · NYU Langone Health Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2027
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with epilepsy and are currently receiving care at the NYU Comprehensive Epilepsy Center, and are willing and able to take part in the study. - Family members of people diagnosed with epilepsy who died suddenly and without a clear explanation, where...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT01858285 · Boston Children's Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2030
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with epilepsy - People who receive care at Boston Children's Hospital Who may not be able to join: - People who already have a known genetic diagnosis that explains their epilepsy - People whose epilepsy has a known cause that has already been iden...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02107989 · National Institute of Neurological Disorders and Stroke (NINDS) Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 March 2028
🇺🇸 US

**Who might be able to join this trial:** **Patients with epilepsy:** - People aged 8 or older who have been evaluated or are being evaluated for epilepsy surgery under one of three specific NIH research protocols (18-N-0066, 11-N-0051, or 16-N-0041) - People with a confirmed diagnosis of focal epilepsy, supported by...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02216500 · University of Florida Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2030
🇺🇸 US

**Who might be able to join this trial:** - People whose doctor has prescribed the ketogenic diet as part of their treatment - People whose blood or lab test results show their body is able to process a diet that is high in fat and low in carbohydrates - People who are likely to be able to follow the treatment as direc...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02531880 · National Institute of Neurological Disorders and Stroke (NINDS) Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 July 2030
🇺🇸 US

Who might be able to join this trial: - Adults between 18 and 60 years of age. - People who are able to give written consent to participate on their own behalf. - People with epilepsy that has not responded to standard anti-seizure treatments for at least one year, with at least one seizure per month on average, and wi...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT02639325 · National Institute of Neurological Disorders and Stroke (NINDS) Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2032
🇺🇸 US

**Who might be able to join this trial:** - People who are 8 years of age or older. - People who have a single brain tumor (either a new tumor or one that has come back) and have also experienced seizures linked to that tumor. The tumor can be identified by a scan rather than surgery. The seizures need to have started...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02821260 · Fondation Ophtalmologique Adolphe de Rothschild Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2028
🇫🇷 FR

Who might be able to join this trial: - Children who have had surgery to treat epilepsy at the Rothschild Foundation in Paris, France. Who may not be able to join: - Children whose parents or guardians are opposed to their child taking part in the study. Important: Always verify eligibility with the trial site direct...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02846272 · The University of Texas Health Science Center, Houston Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2030
🇺🇸 US

"Who might be able to join this trial: - Children who have been diagnosed with intractable epilepsy (a type of epilepsy where seizures are difficult to control with standard treatments) Who may not be able to join: - Children who do not have a diagnosis of intractable epilepsy Important: Always verify eligibility wit...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02890641 · Fondation Ophtalmologique Adolphe de Rothschild Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇫🇷 FR

Who might be able to join this trial: - Children who have epilepsy that has not been controlled by medication, where the seizures start in one specific area of the brain, and where the cause is one of the following conditions: Focal Cortical Dysplasia, Hemimegalencephaly, Tuberous Sclerosis, MOGHE, Hypothalamic Hamarto...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03094312 · Hospices Civils de Lyon Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 23 January 2030
🇫🇷 FR

Who might be able to join this trial: - You are an adult between 18 and 65 years old and are not under any legal guardianship or protection order - You have been diagnosed with focal epilepsy that has not responded well to medication (drug-resistant) - You are already scheduled to have a brain monitoring procedure call...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03233399 · NYU Langone Health Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2027
🇺🇸 US

**Who might be able to join this trial:** - Healthy volunteers who are fluent in English may be eligible to participate. - Patients who have been diagnosed with a psychogenic movement disorder (PMD) or psychogenic non-epileptic seizures (PNES) confirmed by a specialist neurologist may be eligible. - Patients whose tre...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03268824 · Fondation Ophtalmologique Adolphe de Rothschild Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇫🇷 FR

Who might be able to join this trial: - People who have focal epilepsy that has not been controlled by medication (for the main participant group) - People who do not have drug-resistant focal epilepsy (for the comparison/control group) Who may not be able to join: - People with severe intellectual disability (an IQ b...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03400371 · King's College London Not Applicable · 9 countries Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇨🇦 CA🇨🇿 CZ🇩🇰 DK🇪🇪 EE🇫🇷 FR🇮🇹 IT🇳🇴 NO🇬🇧 GB +1 more

**Who might be able to join this trial:** - You have been diagnosed with Juvenile Myoclonic Epilepsy (JME) based on agreed medical guidelines - Your muscle jerking (myoclonus) symptoms first started between the ages of 10 and 25 - Your seizures mainly or only involve jerking of the arms and upper body, especially in th...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03478852 · National Institute of Neurological Disorders and Stroke (NINDS) Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 July 2027
🇺🇸 US

"Who might be able to join this trial: - People who are 8 years of age or older - People who have a known or suspected diagnosis of epilepsy - People who are able to give informed consent themselves, or who have a parent, guardian, or legally authorized representative who is able to give consent on their behalf - Peopl...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03644732 · University Hospital, Grenoble Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2028
🇫🇷 FR

Who might be able to join this trial: - People who have focal epilepsy that has not responded well to medication - People who are already scheduled for a specific type of brain monitoring procedure (called SEEG) as part of planning for possible epilepsy surgery - People who have provided written agreement that they do...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03738072 · University Hospital, Toulouse Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇫🇷 FR

Who might be able to join this trial: - You are between 12 and 65 years old - You are already scheduled to have a procedure called stereo-electro-encephalography (SEEG), which is a type of brain monitoring procedure used to record electrical activity deep in the brain (confirm with trial site) Who may not be able to j...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03819738 · Universitaire Ziekenhuizen KU Leuven Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 10 January 2025
🇧🇪 BE

Who might be able to join this trial: - You must already have a deep brain stimulation system implanted (a device surgically placed in the brain to help control certain conditions) Who may not be able to join: - Children are not eligible for this trial - Pregnant women are not eligible for this trial - Anyone who is u...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03822741 · Children's Hospital of Fudan University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2026
🇨🇳 CN

Who might be able to join this trial: - People who experienced severe seizures as a newborn, or who have a form of epilepsy that causes widespread seizures across the whole body and began in infancy - People whose seizures first started before they were 1 year old - People whose epilepsy or epileptic brain condition ha...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03865771 · University Hospital, Strasbourg, France Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2027
🇫🇷 FR

Who might be able to join this trial: - Children who have had normal physical and mental development for their age - Both parents (and the child, if old enough) must agree to take part by signing a consent form - The child must be covered by a social security (health insurance) scheme - For the epilepsy groups: childre...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03868293 · Brigham and Women's Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 9 March 2027
🇺🇸 US

Who might be able to join this trial: - People who are at least 18 years old - People who have temporal lobe epilepsy that has not been controlled by at least two different anti-seizure medications, as confirmed by a specialist neurologist at Brigham and Women's Hospital - People who have at least 1 to 2 seizures per m...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03893916 · Hospices Civils de Lyon Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 25 April 2029
🇫🇷 FR

Who might be able to join this trial: - People who have had partial epilepsy for at least 2 years, and for whom doctors have decided to either perform surgery to remove the area of the brain causing seizures without first placing electrodes inside the skull, or to place electrodes inside the skull to record brain activ...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03912155 · Assistance Publique Hopitaux De Marseille Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 April 2025
🇫🇷 FR

Who might be able to join this trial: - People who are having electrodes placed inside the brain as part of an assessment to see if surgery could help with epilepsy that has not responded to medication. - People (or their legal representative) who have been informed about the trial and have agreed to take part. - Peop...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03953768 · University of Louisville Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 13 December 2025
🇺🇸 US

**Who might be able to join this trial:** - People who are receiving a vagus nerve stimulator (VNS) implant for the first time as a treatment for epilepsy. - People who have seen a neurologist based in Louisville within the past year, or — for those at the University of Utah or Baylor University sites — people with doc...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04076449 · yuanli Zhao Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇳 CN

Who might be able to join this trial: - People between 18 and 70 years of age - People who have been diagnosed with a single cerebral cavernous malformation (an abnormal cluster of blood vessels in the brain) - People whose affected area of the brain has not previously been treated Who may not be able to join: - Peopl...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04126369 · University Hospital, Grenoble Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 20 January 2026
🇫🇷 FR

**Who might be able to join this trial:** - You have epilepsy that has not been well controlled by medication (also called drug-resistant epilepsy), as defined by international medical guidelines - Your epilepsy treatment has been stable and unchanged for at least 3 months - You do not have any planned surgery coming u...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04134754 · University of Iowa Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2029
🇺🇸 US

**Who might be able to join this trial:** - People who are between 18 and 99 years of age - People who have been diagnosed with epilepsy, or where epilepsy is suspected - People who have been admitted to an Epilepsy Monitoring Unit (EMU) for investigation of their episodes, or who are receiving care at the University o...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04144439 · Sherief Abd-Elsalam Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 December 2028
🇪🇬 EG

"Who might be able to join this trial: - People who have been diagnosed with epilepsy - People who have also been diagnosed with ADHD (Attention Deficit Hyperactivity Disorder) Who may not be able to join: - People who have epilepsy but have not been diagnosed with ADHD Important: Always verify eligibility with the t...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT04204863 · University Hospital, Basel, Switzerland Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2050
🇨🇭 CH

Who might be able to join this trial: - You are 18 years old or older - You have been diagnosed with Status Epilepticus (a serious type of prolonged seizure condition) between the years 2005 and 2023 - You were treated for this condition at either the University Hospital of Basel or the Cantonal Hospital Aarau Who may...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04253379 · CHU de Reims Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 19 October 2026
🇫🇷 FR

Who might be able to join this trial: - Children between 6 and 12 years old who have been diagnosed with epilepsy and whose first language is French - Children in the same age range without epilepsy may also be eligible to take part as a comparison group Who may not be able to join: - Children in the comparison (non-e...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04274179 · Johns Hopkins University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 May 2028
🇺🇸 US

Who might be able to join this trial: - Children who were between 3 and 12 years old when their absence seizures (brief staring or "blank" episodes) started, and whose epilepsy fits the pattern of classic childhood absence epilepsy - Children with normal intelligence or only mild learning difficulties - Children whose...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04289467 · Children's Hospital of Orange County Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇺🇸 US

Who might be able to join this trial: - The child must be between 12 and 36 months old (1 to 3 years old) - The child must have been diagnosed with infantile spasms (a type of seizure disorder in babies and toddlers) - The child must still be having epileptic spasms even after being treated with two standard medication...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04302116 · Kullasate Sakpichaisakul Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇹🇭 TH

**Who might be able to join this trial:** - The baby is between 2 and 14 months old at the time of joining the trial - A specialist children's brain doctor has diagnosed the baby with infantile spasms, and a specialist has confirmed a specific unusual brainwave pattern on a brain activity test (EEG) - The baby is a Tha...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04322734 · Southwest Autism Research & Resource Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇺🇸 US

Who might be able to join this trial: - Children and teenagers with Autism Spectrum Disorder (ASD), confirmed by a recognized diagnostic assessment or evaluation by the lead doctor, who are between birth and 17 years and 11 months old - Children and teenagers between birth and 17 years and 11 months old who have been d...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04419272 · VA Office of Research and Development Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 31 May 2028
🇺🇸 US

Who might be able to join this trial: **People with epilepsy (who may receive the study drug):** - Adults aged 18 or older who have been diagnosed with focal-onset epilepsy (a type of epilepsy where seizures start in one area of the brain), confirmed by a specialist using medical history, brain imaging, and brainwave...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT04421846 · Assistance Publique - Hôpitaux de Paris Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2033
🇫🇷 FR

Who might be able to join this trial: **Group 1 (Status Epilepticus):** - You are 2 years old or older and are experiencing a prolonged or repeated seizure episode (known as status epilepticus) - You are covered by the French social security system (excluding the AME state medical assistance program) - You, or a famil...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04451278 · Fondation Ophtalmologique Adolphe de Rothschild Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2027
🇫🇷 FR

Who might be able to join this trial: - The patient must be between 6 and 18 years old. - The patient must be scheduled to have an MRI scan for epilepsy that has not responded well to medication and has a known physical cause in the brain. - The patient must be covered by a social security or health insurance plan. - T...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04462770 · Epygenix Phase 3 · 9 countries Recruiting
Recruiting Phase 3 Est. completion 1 April 2027
🇨🇦 CA🇬🇪 GE🇭🇺 HU🇮🇳 IN🇵🇱 PL🇷🇴 RO🇪🇸 ES🇬🇧 GB +1 more

**Who might be able to join this trial:** - People who are 2 years of age or older at the time of giving consent to join the study. - People (or their parent or legal guardian) who are willing and able to sign a consent form before any study activities begin. - People who have been diagnosed with Dravet Syndrome (DS)...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04526093 · University Health Network, Toronto Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2028
🇨🇦 CA

Who might be able to join this trial: - People aged 19 or older who have been authorised to use medical cannabis by a healthcare practitioner, whether or not they have used medical cannabis before, and who have given their consent to participate - People whose main reason for using medical cannabis is to help with pain...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04559919 · Sahlgrenska University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2031
🇸🇪 SE

Who might be able to join this trial: - Adults aged 18 years or older - People who have had an unprovoked seizure within the past year, or who have a diagnosis of epilepsy (defined as having had a seizure in the last 10 years, or having been on epilepsy medication in the last 5 years) Who may not be able to join: - Pe...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04649008 · University of Pennsylvania Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 28 February 2027
🇺🇸 US

Who might be able to join this trial: - You have epilepsy that has not been controlled with medication - Your doctors are planning to place recording electrodes inside your skull to monitor brain activity - Your doctors believe your seizures may be coming from the temporal lobe (a specific area of the brain) Who may n...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT04653012 · Institut National de la Santé Et de la Recherche Médicale, France Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 27 February 2029
🇫🇷 FR

**Who might be able to join this trial:** - You have epilepsy that has not been controlled by medication, and the seizures come from a specific area of the brain - You are already scheduled to have electrodes placed inside your skull to help doctors find where your seizures are coming from, as part of pre-surgery testi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04677751 · The University of Texas Health Science Center, Houston Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇺🇸 US

Who might be able to join this trial: - The person has already had the RNS system (a brain stimulation device) surgically implanted. - The person is able to attend and complete 12 weeks of acupuncture sessions. - The person is able to stay on the same medications without changes for 12 weeks. - The person is able to ke...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04715646 · UCB Biopharma SRL Phase 3 · 11 countries Recruiting
Recruiting Phase 3 Est. completion 8 July 2030
🇧🇪 BE🇨🇿 CZ🇫🇷 FR🇩🇪 DE🇭🇺 HU🇮🇹 IT🇯🇵 JP🇲🇽 MX +3 more

**Who might be able to join this trial:** *For people joining from a previous related study (long-term follow-up participants):* - You are at least 1 month old and have a confirmed diagnosis of epilepsy, and previously took part in one of two specific earlier studies (NCT01364597 or NCT03325439) *For people in Japan...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04802135 · Assistance Publique Hopitaux De Marseille Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2029
🇫🇷 FR

Who might be able to join this trial: - The baby must have epilepsy (seizures) that started before they were 1 month old and required starting anti-seizure medication. - The epilepsy must not have a one-off or temporary cause (such as a blood sugar problem or infection). - The epilepsy must not be explained by a struct...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04861051 · Stanford University Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 August 2028
🇺🇸 US

Who might be able to join this trial: - People who are currently admitted to the Stanford Epilepsy Monitoring Unit - People who are over 18 years old Who may not be able to join: - People who have ever been diagnosed with a psychotic disorder or bipolar disorder - People who are not able to speak, read, or understand...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04945213 · Hospital Sirio-Libanes Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 20 December 2026
🇧🇷 BR

**Who might be able to join this trial:** - You have agreed to take part and given your consent to join the study - You are between 18 and 75 years old - Your level of consciousness after the injury was measured at a certain score (between 6 and 12 on a standard scale used in hospitals), or if your score was lower (bet...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04986683 · Wayne State University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇺🇸 US

**Who might be able to join this trial:** **For patients with epilepsy:** - You have epilepsy that has not been controlled by medications (drug-resistant focal epilepsy) - You are between 3 and 19 years old - You are already planned to have a two-stage epilepsy surgery that involves placing electrodes on the surface o...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05019885 · Madeline Fields Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 March 2026
🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older - People who are willing and able to sign and date a consent form agreeing to take part - People who have difficulty with memory or thinking are not automatically excluded from this trial - People who have been diagnosed with drug-resis...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05032105 · Ohio State University Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 December 2025
🇺🇸 US

**Who might be able to join this trial:** - People who have epilepsy that seriously affects their daily life and has not been controlled after trying at least 2 different anti-epileptic medications. - People who have seizures that start in one area of the brain, which may or may not spread to the whole brain. - People...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05066217 · Epygenix Phase 3 · 3 countries Recruiting
Recruiting Phase 3 Est. completion 1 November 2026
🇮🇹 IT🇵🇱 PL🇺🇸 US

**Who might be able to join this trial:** - People aged 2 to 55 years old at the time of screening - People (or their parent or legal guardian) who are willing and able to give written consent to participate - People who have been diagnosed with Lennox-Gastaut Syndrome (LGS), which includes all of the following: evide...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05082181 · NYU Langone Health Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2027
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 or older - People who have been diagnosed with epilepsy for at least one year - People who are fluent in English or Spanish - People who have elevated depressive symptoms, based on a score of 10 or higher on a standard depression questionnaire called the PHQ-9 - Pe...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05085704 · Weill Medical College of Cornell University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2029
🇺🇸 US

**Who might be able to join this trial:** - You are between 16 and 80 years old and are generally in good health, or you have already been diagnosed with a condition called G1D (a genetic disorder confirmed by previous testing, not for this study). - You have dental fillings, dental crowns, or short dental retainer wir...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05096273 · University of Alabama at Birmingham Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 May 2026
🇺🇸 US

**Who might be able to join this trial:** - You are between 9 and 18 years old - A doctor has diagnosed you with psychogenic non-epileptic seizures (a type of seizure not caused by abnormal brain electrical activity) using a specific test called a video-EEG - A family member (a parent, if you are under 18) is willing t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05101161 · ETH Zurich Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 23 September 2026
🇨🇭 CH

Who might be able to join this trial: - People aged 18 or older who are already scheduled to receive a Percept™ PC neurostimulator device as part of their standard medical care - People who are expected to stay in hospital for at least 3 days after the operation Who may not be able to join: - People whose doctors expe...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05135091 · Neurona Therapeutics Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 February 2029
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 to 75 years old, of any gender - People diagnosed with a specific type of epilepsy called mesial temporal lobe epilepsy (MTLE), where seizures start on one side of the brain only - People whose seizures have not been controlled even after trying at least 2 differen...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05140265 · University of New Mexico Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2028
🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older - People whose EEG records can be matched to their electronic medical records at the study hospital (note: those aged 90 and over will have their age recorded as "90 or older" to protect their privacy, and all EEG data will be de-identi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05222594 · Massachusetts General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2027
🇺🇸 US

Who might be able to join this trial: - A multidisciplinary epilepsy surgery team has determined that the person needs brain monitoring involving the left side of the brain. - The person is able to follow instructions and has agreed to take part by giving informed consent. - The person is between 18 and 85 years of age...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05223985 · Alcis Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2024
🇫🇷 FR

**Who might be able to join this trial:** - People aged 18 months to 65 years - People who have epilepsy that focuses in one area of the brain, does not respond well to medication, and significantly affects daily life - People (or their parent or guardian, for minors) who are informed about the study and willing to si...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05254730 · Adrien Peyrache Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2026
🇨🇦 CA

Who might be able to join this trial: - People who have been clinically diagnosed with epilepsy that has not responded to treatment, and who have been assessed as suitable for a brain monitoring procedure called stereoelectroencephalography (sEEG), where small electrodes are placed in the brain to record activity (conf...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05283811 · Baylor College of Medicine Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2027
🇺🇸 US

Who might be able to join this trial: - People between 10 and 64 years old (male or female) who are having electrodes placed inside the skull as part of their epilepsy diagnosis or assessment. Who may not be able to join: - People who are unable to understand and follow instructions during the study. - People who are...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05285059 · Hospices Civils de Lyon Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 21 March 2027
🇫🇷 FR

Who might be able to join this trial: - (Patient group) Children who have epilepsy - (Control group) Children who do not have any neurological, psychiatric, or developmental conditions - (Both groups) A parent or guardian has agreed to the child's participation - (Both groups) The child is registered with the French so...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05289934 · Johns Hopkins University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2027
🇺🇸 US

"Who might be able to join this trial: - Children between 4 and 17 years old who are staying in an Epilepsy Monitoring Unit for up to 7 days may be considered. Who may not be able to join: - Children who do not speak English may not be eligible to participate. Important: Always verify eligibility with the trial site...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05290610 · University of Minnesota Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2027
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years old or older at the time of screening - You are willing and able to sign a consent form agreeing to take part in the study - You are willing to follow all study procedures and are available for the full length of the study - You are already scheduled to have...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05307146 · Universitaire Ziekenhuizen KU Leuven Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2035
🇧🇪 BE

Who might be able to join this trial: - Adults aged 18 or older - People with epilepsy who are already scheduled to have electrodes placed inside the skull as part of their treatment - People who are able to understand what the study involves and provide their own consent to participate Who may not be able to join: -...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05313308 · Clinigen K.K. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2028
🇯🇵 JP

Who might be able to join this trial: - You have been diagnosed with a type of seizure activity that does not involve visible shaking or convulsions (called non-convulsive status epilepticus) - You received the study medication before arriving at a medical facility (such as at home or on the way to hospital) - You rece...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05327387 · University of Southern California Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2026
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older who are being considered for surgery to treat epilepsy that has not responded to medication, or to treat a brain tumor. - People who have had electrodes surgically placed in the brain as part of their standard medical care to locate where seizures beg...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05335187 · Pierre Mégevand Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2027
🇨🇭 CH

Who might be able to join this trial: - People aged 18 or older who have focal epilepsy that has not been controlled by medication. - People who are being considered as a possible candidate for epilepsy surgery. - People whose medical team has determined they need brain monitoring using electrodes placed inside the sku...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05339438 · Central Hospital, Nancy, France Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 9 June 2027
🇫🇷 FR

Who might be able to join this trial: - Adults aged 18 or over - People who are enrolled in or covered by a social security scheme - People who have received full information about how the trial works and have signed a consent form - People who have completed a medical check-up relevant to the trial before taking part...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05353452 · Wake Forest University Health Sciences Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 19 May 2026
🇺🇸 US

**Who might be able to join this trial:** - People who are willing to sign and date a consent form agreeing to take part in the study - People who are willing to follow all of the study's procedures throughout the trial - People who have been diagnosed with post-traumatic epilepsy — meaning a neurologist has diagnosed...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05374824 · Ann & Robert H Lurie Children's Hospital of Chicago Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2025
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with Lennox-Gastaut syndrome (a severe form of epilepsy that begins in childhood) and have medical records at one of the participating pediatric centers involved in this trial **Who may not be able to join:** - People who do not have a diagnosi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05393518 · University Hospital, Bordeaux Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 11 October 2026
🇫🇷 FR

**Who might be able to join this trial:** - You are a man or woman between 18 and 65 years old - You have epilepsy that has not been controlled by medication (drug-resistant epilepsy) - You are already scheduled for a specific type of pre-surgery brain assessment that involves placing electrodes inside the brain to rec...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05406349 · Boston University Charles River Campus Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2027
🇺🇸 US

Who might be able to join this trial: - You are between 18 and 70 years old - You have good enough vision and hearing to complete memory and thinking tests - You have had electrodes placed deep in your brain for epilepsy evaluation or treatment, OR you have a NeuroPace RNS device (a brain implant) that was put in to tr...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05416684 · RenJi Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2027
🇨🇳 CN

Who might be able to join this trial: - People who have a gap or hole in their skull that is larger than 3 centimetres across - People who have not had any bleeding in the brain, dangerous pressure in the brain, or fluid build-up in the brain for more than 1 month after their previous surgery (or where these issues hav...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05418894 · Baylor College of Medicine Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2027
🇺🇸 US

**Who might be able to join this trial:** - Men and women (not currently pregnant) between the ages of 22 and 70 - People who have been formally diagnosed with major depressive disorder (MDD) as their main diagnosis, currently experiencing a depressive episode, without any psychotic features - People whose current dep...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05420935 · Assistance Publique - Hôpitaux de Paris Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 12 April 2033
🇫🇷 FR

**Who might be able to join this trial:** - People aged between 18 and 70 years old - People who had an allergic reaction during surgery at any point in the last 10 years, regardless of how severe it was, what caused it, or what type of anaesthetic was used - People who have already attended a combined allergy and ana...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05431595 · M.D. Anderson Cancer Center Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 2 February 2027
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with advanced cancer that has spread, cannot be cured, or has come back - You are currently being seen by a palliative care team while in the hospital - You have been diagnosed with delirium (a state of sudden confusion) according to standard medical...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05450822 · Gitte Moos Knudsen Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇩🇰 DK

**Who might be able to join this trial:** **For healthy volunteers:** - You have no history of mental health conditions or other major health problems **For patients (Cohort I – first seizure group):** - You are between 16 and 55 years old - You have had a first seizure that strongly suggests epilepsy, but you do not...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05450978 · University of Pittsburgh Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2027
🇺🇸 US

**Who might be able to join this trial:** - Women with epilepsy between the ages of 18 and 45 who are either planning to become pregnant or are in the very early stages of pregnancy (early first trimester) - Women with epilepsy who are able to keep a daily medical diary - Women with epilepsy who are able to fill out qu...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05459090 · Neuromed IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 February 2025
🇮🇹 IT

**Who might be able to join this trial:** - People who have temporal lobe epilepsy that has not responded to medication (sometimes called drug-resistant epilepsy). **Who may not be able to join:** - People whose temporal lobe epilepsy is caused by a stroke, reduced blood flow to the brain (ischemia), a type of blood v...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05459597 · Wei Zhao Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 March 2028
🇨🇳 CN

Who might be able to join this trial: - You are 65 years old or older - You have been diagnosed with epilepsy - You are currently taking medication to treat epilepsy Who may not be able to join: - You are not expected to survive beyond the next 48 hours - You have a known allergy to epilepsy medications - You are curr...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05485649 · University Health Network, Toronto Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇨🇦 CA

**Who might be able to join this trial:** - You are a woman with epilepsy who has been seen at the Toronto Western Hospital Epilepsy Clinic at any time since June 1st, 2022 - You were pregnant at some point between June 1st, 2022 and June 1st, 2024 - You have been formally diagnosed with epilepsy according to standard...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05493722 · University of Minnesota Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 15 January 2028
🇺🇸 US

Who might be able to join this trial: - People who have epilepsy that has not been controlled by medical treatments - People who already have a deep brain stimulator device surgically implanted Who may not be able to join: - People who have severe dementia, as assessed by the trial investigator Important: Always veri...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT05503290 · University Health Network, Toronto Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2026
🇨🇦 CA

Who might be able to join this trial: - People who are at least 18 years old - People who are currently pregnant with their first child - People who are able to give their consent to take part in the study - People who have access to the internet - People who have a confirmed epilepsy diagnosis, based on a brain wave t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05527093 · Assistance Publique - Hôpitaux de Paris Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 19 January 2029
🇫🇷 FR

Who might be able to join this trial: - Adults aged 18 or older - People who can read and speak French well - People who have given written agreement to take part in the trial - People who have had focal temporal lobe epilepsy (a type of epilepsy affecting one area of the brain) for at least one year, which has not bee...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05529264 · Dartmouth-Hitchcock Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2027
🇺🇸 US

**Who might be able to join this trial:** **Group 1 – People with electrodes placed inside the skull (Intracranial EEG):** - You are 18 years of age or older (there is no upper age limit) - You have been diagnosed with epilepsy that has not responded well to treatment, and you are already having brain wave monitoring...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05534672 · Katarzyna Kotulska Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 June 2027
🇵🇱 PL

Who might be able to join this trial: - You (or your child) must be between 3 months and 50 years old at the time of joining the trial - You (or your child's parent/caregiver) must be willing and able to give written agreement to take part in the study - You (or your child's parent/caregiver) must be willing and able t...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05559749 · Wake Forest University Health Sciences Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 19 February 2026
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older, of any gender - People who have been diagnosed with epilepsy, based on a neurologist's assessment or brainwave test (EEG) results - People who are experiencing symptoms of anxiety or depression - People who are currently receiving neurological care a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05594017 · University of Texas Southwestern Medical Center Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 30 November 2026
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 to 55 years, of any race, ethnicity, or gender - People whose treating doctor has already decided, as part of their normal medical care, that they need pre-surgery brain monitoring using internal electrodes and a stay in an Epilepsy Monitoring Unit - People wh...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT05600738 · The University of Texas Health Science Center, Houston Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2027
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with epilepsy - You already have an implanted brain stimulation device being used as part of your treatment (such as a Deep Brain Stimulator or Responsive Neurostimulation device) - You are currently being seen and monitored at an outpatient epilepsy clini...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05608408 · Nitin Tandon Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2029
🇺🇸 US

**Who might be able to join this trial:** - People who have been assessed by a team of clinicians and are thought to have a specific type of epilepsy affecting a region of the brain called the hippocampus (referred to as EPH in the trial). - People who are able to follow test instructions and give their informed agree...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05609084 · Assistance Publique Hopitaux De Marseille Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 March 2027
🇫🇷 FR

**Who might be able to join this trial:** - People aged 16 years or older - People whose seizure-producing area involves the temporal region of the brain that controls language - People whose brain's language-dominant side has already been identified through prior testing - People who are due to have surgery to remove...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05632978 · Cardiff and Vale University Health Board Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2032
🇬🇧 GB

"Who might be able to join this trial: - People who are being investigated for epilepsy and are receiving clinical care through the epilepsy unit at Cardiff & Vale University Health Board, or through regional clinics in Cwm Taf. - People who are at least 16 years old. - People who are willing and able to give their inf...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05637086 · Mostafa Bahaa Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 20 December 2026
🇪🇬 EG

**Who might be able to join this trial:** - You are 18 years old or older - You have been diagnosed with grand mal epilepsy (a type of epilepsy involving full-body seizures) and are being treated with phenytoin as your only seizure medication - If you are a woman, you must either test negative for pregnancy before join...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05651204 · Cook Children's Health Care System Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 8 September 2024
🇺🇸 US

**Who might be able to join this trial:** - A parent or caregiver must be willing and able to give permission for the child to take part, and if the child is old enough to understand, they should also agree to participate. - The participant and their parent or caregiver must be willing and able to follow all the requi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05664464 · University of Zurich Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2026
🇨🇭 CH

**Who might be able to join this trial:** - People who have been newly diagnosed with a type of brain tumour called glioblastoma (located in the upper part of the brain), diagnosed according to the 2021 WHO brain tumour classification system - People who are able to give their signed consent to take part - People who...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05664854 · University College, London Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2027
🇬🇧 GB

Who might be able to join this trial: - Adults aged 18 or older - People who are able to provide written agreement to participate, either personally or through someone acting on their behalf - People who have been clinically diagnosed with a condition that is directly or indirectly affected by, or may potentially respo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05670847 · Sohag University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 June 2025
🇪🇬 EG

Who might be able to join this trial: - People who have epilepsy that has not responded to treatment (sometimes called drug-resistant epilepsy) - People who are having 7 or more seizures per week Who may not be able to join: - People who are unable or unwilling to give informed consent to participate - People who have...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05673915 · Mayo Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a type of epilepsy that affects the whole brain, a specific part of the brain, or a sleep-related form of epilepsy involving brain activity disruptions. - You have at least 2 seizures per month that can be counted and tracked, or your brain activi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05674552 · Sohag University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 June 2025
🇪🇬 EG

**Who might be able to join this trial:** - People who have generalised convulsive status epilepticus (a prolonged, severe seizure or repeated seizures without recovery) that has not responded to standard treatments **Who may not be able to join:** - People for whom informed consent has not been obtained - People who...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05688683 · Fondation Ophtalmologique Adolphe de Rothschild Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2028
🇫🇷 FR

Who might be able to join this trial: - People who are already scheduled to have brain surgery while awake, which involves recording electrical activity from inside the brain. Who may not be able to join: - People who are completely deaf. - People who have a condition or difficulty that, in the doctor's judgment, woul...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05724719 · Dr. Gavin Winston Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇨🇦 CA

Who might be able to join this trial: - Adults between the ages of 18 and 65 who have had a single, unprovoked seizure and are being seen at a First Seizure Clinic in Halifax or Kingston. - Healthy volunteers who are a similar age, sex, and education level to the seizure patients may also be considered for a comparison...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05737784 · Praxis Precision Medicines Phase 2 · 2 countries Recruiting
Recruiting Phase 2 Est. completion 1 August 2025
🇧🇷 BR🇺🇸 US

Who might be able to join this trial: - The person had their first seizure before they were 3 months old. - The person weighs at least 10 kilograms (approximately 22 pounds) at the time of screening. - The person has had genetic testing done by an approved laboratory that confirmed a change (variant) in a gene called S...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05755919 · Wayne State University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 February 2027
🇺🇸 US

Who might be able to join this trial: - People who are scheduled to have epilepsy surgery that involves recording brain activity from inside the skull, using electrodes placed on the brain's surface or deeper within the brain. Who may not be able to join: - People who have a cancerous brain tumour, or a progressive br...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05794295 · University of California, Davis Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇺🇸 US

Who might be able to join this trial: - Adults between 18 and 40 years old - People who have been diagnosed with focal epilepsy (a type of epilepsy where seizures start in one specific area of the brain) - People who are able to fully cooperate and follow instructions during the trial - People who do not have any other...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05819268 · University of Alabama at Birmingham Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇺🇸 US

Who might be able to join this trial: - People between the ages of 11 and 18 years old - People who have been diagnosed with functional seizures - People who have internet access, as sessions and program activities take place online Who may not be able to join: - People who also have epilepsy alongside their functiona...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05845255 · MJN Neuroserveis, S.L Not Applicable · 3 countries Recruiting
Recruiting Not Applicable Est. completion 30 December 2024
🇩🇪 DE🇪🇸 ES🇬🇧 GB

Who might be able to join this trial: - People aged 12 to 65 years old at the time of signing the consent form. - People who have been diagnosed with drug-resistant epilepsy (meaning seizures have not been controlled with medication), with focal, generalised, or mixed seizure types, confirmed by an epilepsy specialist....

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05854160 · University of Alabama at Birmingham Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 February 2026
🇺🇸 US

Who might be able to join this trial: - People who are having small electrodes (called sEEG electrodes) placed in the brain as part of a standard evaluation for epilepsy surgery - People who have the cognitive ability to perform simple tasks and follow basic instructions - People whose electrodes are placed in two spec...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05863910 · University of Manitoba Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇨🇦 CA

Who might be able to join this trial: - The participant must be between 3 and 17 years old - They must have an official document from a doctor, nurse practitioner, or other healthcare provider that allows them to use medical cannabis - The medical cannabis must have been authorized to help with pain, sleep, mood, behav...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05864547 · Norwegian University of Science and Technology Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2030
🇳🇴 NO

Who might be able to join this trial: - You are having your first-ever stroke and are being treated at the stroke unit at St. Olavs Hospital - Before this stroke, you were largely independent in daily life with little to no disability (confirm with trial site) - You are able to understand and agree to take part in the...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05865561 · Fondation Ophtalmologique Adolphe de Rothschild Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 24 June 2026
🇫🇷 FR

**Who might be able to join this trial:** - People aged 18 or older - People who have epilepsy that has not responded well to medication, as defined by international epilepsy guidelines - People who experience one of these three types of seizures: focal seizures (seizures that start in one part of the brain), focal sei...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05871372 · Baylor College of Medicine Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2028
🇺🇸 US

Who might be able to join this trial: - Adults with epilepsy who are already scheduled to have monitoring devices placed inside the skull to track seizures, and who have given their informed consent to participate - People who are already enrolled in a separate deep brain stimulation (DBS) trial for depression at the s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05885646 · University Hospital, Angers Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇫🇷 FR

Who might be able to join this trial: - People who have been diagnosed with a childhood epilepsy syndrome that becomes more active during sleep - People whose epilepsy has not been adequately controlled after trying at least two different anti-epileptic medications - People who have had a sleep brainwave test (EEG) don...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05927974 · University of Alabama at Birmingham Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 27 March 2027
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with epilepsy that has not responded to medical treatment - People whose case has been reviewed by a team of specialists who agree that surgery is an appropriate option - People who are 18 years of age or older - People who are willing to take part...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05928598 · University of Michigan Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇺🇸 US

Who might be able to join this trial: **For patients:** - Adults who have epilepsy that has not responded well to medications (known as drug-resistant epilepsy) - People who are receiving care through the Epilepsy clinics at the University of Michigan **For healthcare providers:** - Epilepsy care providers who work a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05944692 · CREmedical Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 3 August 2026
🇺🇸 US

**Who might be able to join this trial:** - Children aged 6 years old up to (but not including) 18 years old (at the Boston Children's Hospital site), or adults aged 18 years and older (at the Barrow Neurological Institute site) - People who are able to sign a written consent form, or who have a legal representative a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05981755 · The University of Texas Health Science Center, Houston Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2028
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with focal epilepsy that has not been controlled by treatment - People who have been admitted to the Epilepsy Monitoring Unit at Memorial Hermann-Texas Medical Center for an invasive brain monitoring procedure using electrodes placed on or in the br...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05989893 · The University of Texas Health Science Center, Houston Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2028
🇺🇸 US

**Who might be able to join this trial:** - You have epilepsy that has not been controlled by medication, and you are planning to have (or have already had) electrodes placed on or in the brain to find where seizures start and to identify important areas for speech and movement - You have epilepsy, a brain tumor, or an...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05992402 · Kayela Arrotta Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2028
🇺🇸 US

**Who might be able to join this trial:** - Adults between 18 and 60 years old who have been diagnosed with epilepsy and whose epilepsy specialist has confirmed them as a suitable candidate for surgery - People who are able to give their own consent to participate without assistance - People who are fluent in English -...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05996900 · Stanford University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2027
🇺🇸 US

**Who might be able to join this trial:** - You are a man or woman between 18 and 65 years old - You have epilepsy that has not been controlled by medication and your doctors need to do advanced monitoring (called phase II monitoring) to better understand your seizures - You are able to understand what the study involv...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06007053 · University of Alabama at Birmingham Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇺🇸 US

Who might be able to join this trial: - People aged 11 to 18 years old. - People who have been diagnosed with psychogenic non-epileptic seizures (PNES) by a doctor, confirmed using a video-EEG test. - People who have a family member (such as a parent or guardian for those under 18) who is willing to take part and whom...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06016686 · University of Minnesota Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 December 2026
🇺🇸 US

Who might be able to join this trial: - People who are between 18 and 40 years of age - People who speak English - People who have Medicare or equivalent health insurance from a partner country Who may not be able to join: - People who are currently pregnant - People who smoke and are not willing to avoid smoking on t...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06022055 · Assistance Publique - Hôpitaux de Paris Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 February 2030
🇫🇷 FR

Who might be able to join this trial: - People aged 18 years or older - People who have focal epilepsy that has not been controlled by medication - People who are admitted to hospital for pre-surgery evaluation or to have epilepsy surgery - People who have given their own consent to take part, or whose legal representa...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06027749 · Epitel, Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 March 2025
🇺🇸 US

Who might be able to join this trial: - People who have a history of seizures (whether epileptic, non-epileptic, or unknown type) - People who experience at least one seizure every two weeks - People whose doctor has already arranged a take-home (ambulatory) EEG brain monitoring test as part of their regular care - Peo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06038929 · Mayo Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2027
🇺🇸 US

Who might be able to join this trial: - You must be at least 18 years old. - You must be able to understand and sign a consent form agreeing to take part in the study. - You have been diagnosed with epilepsy that has not responded well to medications, and you already have a vagus nerve stimulator (VNS) device implanted...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06052605 · Anny Reyes Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2030
🇺🇸 US

Who might be able to join this trial: **For the Patient Survey (Part 1a) and Part 3:** - People who have been diagnosed with epilepsy by a neurologist, epileptologist, or a general/family doctor - People who are 55 years of age or older (up to 89 years old) - People who consider themselves able to communicate in Engli...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06053671 · King's College Hospital NHS Trust Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 8 April 2025
🇬🇧 GB

Who might be able to join this trial: - Both adults and children (male and female) may be eligible - People who have been diagnosed with Focal Cortical Dysplasia Type IIA or IIB (a specific brain condition linked to epilepsy) — either confirmed through tissue testing, or suspected based on brain scans and other tests w...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06059157 · Cliniques universitaires Saint-Luc- Université Catholique de Louvain Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2026
🇧🇪 BE

Who might be able to join this trial: - People who have epilepsy that has not responded well to medication (sometimes called drug-resistant epilepsy) - People who have already been chosen by their medical team to undergo a procedure called SEEG (stereo-electroencephalography), which involves placing small electrodes in...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06079294 · Assistance Publique - Hôpitaux de Paris Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2026
🇫🇷 FR

**Who might be able to join this trial:** - People who are 18 years of age or older - People who have been newly diagnosed with autoimmune encephalitis, meeting at least one of the following: a confirmed diagnosis of "definite limbic autoimmune encephalitis," a "possible autoimmune encephalitis" diagnosis along with a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06092125 · Xuanwu Hospital, Beijing Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 October 2025
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with mild cognitive impairment (early memory and thinking problems) or Alzheimer's disease, rapid eye movement sleep behavior disorder (a condition where people act out their dreams), Parkinson's disease, epilepsy, or a malignant (cancerous) brain t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06092320 · University of British Columbia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2025
🇨🇦 CA

Who might be able to join this trial: - People who are currently enrolled as second-year medical students at the University of British Columbia. Who may not be able to join: - There are no listed exclusion criteria for this trial. Important: Always verify eligibility with the trial site directly before applying.

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06097195 · Neuronostics Ltd Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2026
🇬🇧 GB

Who might be able to join this trial: - You are 18 years old or older and have had what appears to be your first seizure or seizures - You are able to understand and agree to take part in the study (give informed consent) - Your doctor has decided to refer you for a brainwave test (EEG) based on your medical history an...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06105645 · University Hospital, Toulouse Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2030
🇫🇷 FR

Who might be able to join this trial: - You have epilepsy that has not been controlled by medication (called drug-resistant focal epilepsy), as defined by the International League Against Epilepsy, and you are already scheduled to have a brain monitoring procedure called SEEG (where small electrodes are placed in the b...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06132893 · Biohaven Therapeutics Ltd. Phase 3 · 14 countries Recruiting
Recruiting Phase 3 Est. completion 1 December 2026
🇦🇷 AR🇦🇹 AT🇧🇪 BE🇨🇱 CL🇭🇷 HR🇨🇿 CZ🇫🇷 FR🇭🇺 HU +6 more

**Who might be able to join this trial:** - You are between 18 and 75 years old - You have been diagnosed with a type of epilepsy called "focal onset epilepsy" for at least 1 year before the study screening - Your focal seizures fall into one of these types: seizures where you stay aware but have noticeable signs or s...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06202196 · University Hospital, Montpellier Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 16 April 2028
🇫🇷 FR

Who might be able to join this trial: - People who are between 18 and 60 years old - People who have epilepsy that is poorly controlled, meaning seizures have continued for more than a year despite receiving appropriate treatment - People who have been seizure-free for more than a year, but where the treating doctor co...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06202976 · Imagine Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 13 September 2033
🇫🇷 FR

Who might be able to join this trial: - The person must be under 18 years of age at the time of joining the trial. - The person must have one of two specific types of epilepsy: either a treatment-resistant focal epilepsy linked to a visible brain abnormality, or a rare type of epilepsy where no brain abnormality is vis...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06205160 · Neurosoft Bioelectronics SA Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2027
🇳🇱 NL

Who might be able to join this trial: - People who are 18 years of age or older at the time of joining the trial - People who have epilepsy caused by a brain lesion (including a specific type called secondary mesial temporal sclerosis) where doctors are planning to use specialised recording equipment directly on the br...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06210022 · IRCCS San Raffaele Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2027
🇮🇹 IT

**Who might be able to join this trial:** *For all participants:* - People who are native Italian speakers with Italian as their only language - People aged between 18 and 60 years old - People with normal vision, or vision that is fully corrected with glasses or contact lenses - People who have given written and verb...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06212609 · Centre Hospitalier Universitaire, Amiens Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇫🇷 FR

Who might be able to join this trial: - Children and teenagers between 1 and 18 years old (male or female) who have partial epilepsy that has not responded well to treatment and whose doctors are considering surgery as a possible option. - People whose epilepsy has not been controlled despite trying at least two differ...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06213090 · Richard Frye Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2030
🇺🇸 US

**Who might be able to join this trial:** - People who have been identified as having neurodevelopmental delays - People who have a clinical visit scheduled at or attending a Rossignol Medical Center **Who may not be able to join:** - No specific exclusion criteria have been listed for this trial (confirm with trial s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06248333 · Xuanwu Hospital, Beijing Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - You are between 14 and 65 years old (inclusive) at the time of your screening visit. - Your seizures have not been controlled well enough by anti-seizure medications. - You have been diagnosed with a type of epilepsy where seizures start in a specific area of the brain and m...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06262594 · University of Manitoba Phase 3 · 2 countries Recruiting
Recruiting Phase 3 Est. completion 18 April 2026
🇨🇦 CA🇺🇸 US

**Who might be able to join this trial:** - You have epilepsy that is focused in one part of the brain and is linked to sleep (known as sleep-related focal epilepsy) - You are using an effective form of contraception (birth control) **Who may not be able to join:** - Your epilepsy medication has been changed in the mo...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06263920 · Lancashire Teaching Hospitals NHS Foundation Trust Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 12 January 2027
🇬🇧 GB

**Who might be able to join this trial:** **If you have had a seizure or epilepsy diagnosis (Case group):** - You have been diagnosed with epilepsy of unknown cause, or have had a first seizure, after the age of 18. - Your diagnosis was confirmed at a specialist neurology centre. - Places may be limited to the first 1...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06266234 · Assistance Publique - Hôpitaux de Paris Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2026
🇫🇷 FR

Who might be able to join this trial: - People who have experienced spasms and had a video EEG recording (a brain activity test recorded with video) carried out at one of the participating medical centres - People who are affiliated with social security (a French social insurance system) - People whose legal guardian o...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06271785 · University Hospital, Angers Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 November 2026
🇫🇷 FR

Who might be able to join this trial: - Children and young people aged 2 years old up to (but not including) 17 years old - People who have focal epilepsy that has not been controlled by at least 2 different seizure medications that were properly tried - People who have already had a pre-surgery evaluation — including...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06275685 · Empatica, Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with epilepsy or are considered at risk of developing epilepsy - You (or your parent or guardian, if you are a minor) understand what the study involves and agree to take part - You (or your parent or guardian) can read and communicate in English - You...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06278428 · Number 2 Children's Hospital, Ho Chi Minh City Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2028
🇻🇳 VN

Who might be able to join this trial: - The child has been diagnosed with one of the following specific epilepsy conditions: Early infantile developmental and epileptic encephalopathy, Epilepsy of infancy with migrating focal seizures, Infantile spasms syndrome, Severe myoclonic epilepsy of infancy, or Epilepsy with my...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06280092 · Sanjeet S. Grewal Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 March 2026
🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older (and no older than 75) - People who have epilepsy that has not been controlled by medication, as defined by the International League Against Epilepsy (confirm with trial site) - People who are scheduled to have a specific type of brain...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT06292299 · NHS Greater Clyde and Glasgow Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇬🇧 GB

**Who might be able to join this trial:** This trial has three separate groups, each with different criteria: **Group 1 – Sleep study (overnight cardiorespiratory polysomnography) group:** - People from birth up to and including 16 years of age who are scheduled for an overnight sleep and breathing study - People who...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06292494 · Taipei Veterans General Hospital, Taiwan Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇹🇼 TW

**Who might be able to join this trial:** - People aged 20 or older. - People who have epilepsy that is limited to one area of the brain and has not responded to the maximum doses of at least two different seizure medications. - People who have kept records of their seizure frequency for at least one month before the...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06304389 · Cliniques universitaires Saint-Luc- Université Catholique de Louvain Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2023
🇧🇪 BE

Who might be able to join this trial: **For patients:** - People who have had a VNS (vagus nerve stimulator — a small device implanted in the body to help control nerve activity) for at least 3 months - People aged between 18 and 60 years - People with an IQ above 55 as measured by the Wechsler scale, meaning those wi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06321822 · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 2 August 2025
🇮🇹 IT

**Who might be able to join this trial:** - People of any age (children and adults) who have been diagnosed with epilepsy - People of any sex - People who are currently being seen at the pediatric or adult epilepsy and electroencephalography clinics at U.O.C. Neurophysiopathology - IRCCS Ca' Granda Fondazione Ospedale...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06334029 · IRCCS Eugenio Medea Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 22 November 2026
🇮🇹 IT

Who might be able to join this trial: - People who have been diagnosed with focal or generalized epilepsy, confirmed by a specialist. - People who have had at least one MRI brain scan that includes a type of image called a T1-weighted (T1w) scan. - People who have had at least one resting-state EEG recording (a brain w...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06334952 · Assistance Publique Hopitaux De Marseille Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 18 December 2026
🇫🇷 FR

**Who might be able to join this trial:** - You (or your parent or legal guardian) are willing and able to give written consent to participate - You are 9 years old or older - You have epilepsy that has not been controlled by medications, where the seizures start in one area of the brain, and either surgery is not an...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06362161 · University of Alabama at Birmingham Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2028
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with Functional Neurological Disorder (FND) - You can read and write English fluently - You have been referred to outpatient physical, occupational, or speech therapy for FND at UAB - You have been referred to outpatient psychiatry treatment for FND at UAB...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06380192 · Imagine Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇫🇷 FR

Who might be able to join this trial: - You (or your child) have been diagnosed with Developmental and Epileptic Encephalopathy, which is a condition involving both developmental difficulties and seizures. - You (or your child) are registered with or covered by a social security or health insurance scheme. Who may not...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06383689 · University Hospital, Bonn Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2026
🇩🇪 DE

"Who might be able to join this trial: - You must be eligible for pre-surgical epilepsy testing/evaluation (a process used to assess whether surgery could help treat epilepsy). Who may not be able to join: - Anyone who does not meet the requirements for the pre-surgical epilepsy evaluation procedure cannot join (confi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06388161 · Shen Chun-Hong Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with new focal epileptic seizures or epilepsy, and your first seizure happened within the last 12 months - You are being seen as a regular patient at an epilepsy clinic or epilepsy center - There is no strong suspicion that your seizures are caused by...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06388174 · Shen Chun-Hong Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are a patient at an epilepsy center who has either recently been diagnosed with epilepsy or has an existing epilepsy diagnosis. - You have been diagnosed with a specific type of epilepsy called idiopathic generalized epilepsy (a form of epilepsy with no known structural c...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06388707 · NaviFUS Corporation Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with temporal lobe epilepsy that has not been controlled by trying at least two different seizure medications (used properly and at adequate doses) - Your seizures start in a focused area of the brain, and you have no...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06422923 · Neurona Therapeutics Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 15 June 2027
🇺🇸 US

**Who might be able to join this trial:** - You are between 18 and 75 years old - If you are able to have children, you are willing to use highly effective birth control during the trial - You have a confirmed history of seizures that start in the hippocampus (a part of the brain), with seizure activity detected on bo...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06425029 · Dartmouth-Hitchcock Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇺🇸 US

Who might be able to join this trial: - Adults with epilepsy that has not been controlled by medication, who have had a specific brain stimulation device (called RNS) implanted at least six months ago, and whose treating doctor considers their stimulation settings to be stable - People who are willing to attend all sch...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06432907 · Research Center of Neurology, Russia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 25 December 2026
🇷🇺 RU

**Who might be able to join this trial:** - You have had special brain recording electrodes (called stereoEEG electrodes) placed in your brain for medical reasons - You are willing to give your informed consent to take part in the study - You are between 18 and 70 years old **Who may not be able to join:** - You do no...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06453759 · Great Ormond Street Hospital for Children NHS Foundation Trust Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2028
🇬🇧 GB

Who might be able to join this trial: - Children who are already scheduled to have a procedure called SEEG (a brain monitoring technique used to help plan epilepsy surgery) as part of their pre-surgery assessment at Great Ormond Street Hospital (GOSH) - The child's parent or legal guardian (or the child themselves, whe...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06455384 · Unity Health Toronto Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2027
🇨🇦 CA

Who might be able to join this trial: - Adults aged 18 or older who have been referred to a participating doctor at Mount Sinai Hospital for genetic testing - Parents or legal guardians aged 18 or older whose child has been referred to a participating doctor at SickKids for genetic testing Who may not be able to join:...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06466681 · University Hospital, Lille Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 9 March 2027
🇫🇷 FR

**Who might be able to join this trial:** - People who are older than 18 and younger than 80 years of age - People who have focal epilepsy (a type of epilepsy that starts in one area of the brain) and are already scheduled for a 5-day hospital stay as part of a pre-surgery assessment - People whose general thinking and...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06483061 · University of Alberta Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2029
🇨🇦 CA

**Who might be able to join this trial:** - You are a healthy person aged 18 to 64 with no known health conditions - You are aged 18 to 64 and have been diagnosed with temporal lobe epilepsy, with scarring in a part of the brain called the hippocampus that has been seen on an MRI scan **Who may not be able to join:**...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06492720 · NaviFUS Corporation Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇹🇼 TW

**Who might be able to join this trial:** - You are 18 years old or older - You have epilepsy that has not been controlled despite trying at least 3 different seizure medications, and you are currently taking 1 to 4 seizure medications - Doctors have already done thorough testing to identify where in the brain your sei...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06498362 · University Hospital, Strasbourg, France Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2025
🇫🇷 FR

Who might be able to join this trial: - Children aged between 3 months and 17 years old - Children who received levetiracetam or phenytoin as a second treatment after benzodiazepines did not work for their seizures - Children who were treated at one of the participating hospitals between November 1, 2019 and May 31, 20...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06504511 · NHS Greater Glasgow and Clyde Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇬🇧 GB

"Who might be able to join this trial: - You (or your legal representative) must be willing and able to give consent to take part in the study. - You and your parent or caregiver must be willing and able to follow all the requirements of the study, including attending virtual (online) appointments. - You must have a co...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06524479 · Xuanwu Hospital, Beijing Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 7 June 2026
🇨🇳 CN

Who might be able to join this trial: - People who have focal epilepsy that has not been controlled by medication (sometimes called drug-resistant epilepsy) - People for whom doctors have determined that a type of brain monitoring called SEEG (where small electrodes are placed in the brain) is appropriate as part of pl...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06537986 · Post Graduate Institute of Medical Education and Research, Chandigarh Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 6 January 2025
🇮🇳 IN

Who might be able to join this trial: - You are between 18 and 45 years old - You are any gender - You are willing to take part and sign a consent form agreeing to participate Who may not be able to join: - You have been diagnosed with another condition affecting the brain or nervous system - You are currently taking...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06545214 · Hospices Civils de Lyon Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 4 January 2027
🇫🇷 FR

Who might be able to join this trial: **For people with epilepsy:** - Willingness to give written consent and ability to follow the study requirements - Between 18 and 55 years old - Diagnosed with focal epilepsy (a type of epilepsy where seizures start in one specific area of the brain) - Epilepsy that has not respon...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06545643 · Duke University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2027
🇺🇸 US

Who might be able to join this trial: - People who are older than 18 years of age - People who have at least 2 seizures per week, as recorded in their medical notes - People whose seizure medications are expected to remain unchanged throughout the study period - People whose brain wave patterns (specifically, at least...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06545708 · Hospices Civils de Lyon Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2026
🇫🇷 FR

Who might be able to join this trial: - The child is between 5 and 14 years old - Parents or guardians do not object to the child taking part in the study - The child does not have a major cognitive impairment and is able to understand and follow instructions - The child is covered by a social security scheme (health i...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06550726 · Chinese University of Hong Kong Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2027
Hong Kong

**Who might be able to join this trial:** - People who have been diagnosed with focal epilepsy (a type of epilepsy that starts in one specific area of the brain) that has not responded to medication, where at least two of the following point to the same area of the brain: the pattern of seizures, brainwave testing (EE...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06551090 · Columbia University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with, or are suspected to have, epilepsy that originates in the temporal lobe of the brain. - People who speak English or Spanish fluently, or as their native language. - For people having a specific type of brain monitoring procedure (called sE...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06555965 · Children's Hospital of Philadelphia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 August 2028
🇺🇸 US

**Who might be able to join this trial:** - People of any age, either male or female, may be considered. - People who have a confirmed mutation in either the STXBP1 or SYNGAP1 gene, where that mutation has been classified as causing their condition based on clinical and genetic assessment criteria. Past genetic test re...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06557720 · Xijing Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 11 June 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who are 18 years of age or older - People who have been diagnosed with drug-resistant epilepsy according to the 2010 International League Against Epilepsy (ILAE) criteria - People who have had epilepsy for at least 2 years, with seizures happening at least twice per mo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06570954 · University of Alabama at Birmingham Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2027
🇺🇸 US

Who might be able to join this trial: - You are 19 years of age or older - You have been diagnosed with psychogenic non-epileptic seizures (seizures that are not caused by abnormal electrical activity in the brain) by a doctor, confirmed through a brain monitoring test with video recording (video-EEG) Who may not be a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06579573 · Ono Pharmaceutical Co., Ltd. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 January 2027
🇯🇵 JP

**Who might be able to join this trial:** - You are Japanese, aged 12 years or older, regardless of gender - You have been diagnosed with a type of epilepsy called "Primary Generalized Tonic-Clonic (PGTC) seizures" linked to a condition known as idiopathic generalized epilepsy - You have had at least 5 of these tonic-c...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06585605 · Boston Children's Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2029
🇺🇸 US

**Who might be able to join this trial:** - Your child is between 0 and 18 years old AND has been diagnosed with a movement disorder AND has a confirmed or likely harmful change (variant) in one of a specific list of genes identified by genetic testing (confirm with trial site for the full gene list) **Who may not be...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06590896 · Ono Pharmaceutical Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 January 2027
🇯🇵 JP

Who might be able to join this trial: - You must have fully completed the previous related clinical study called YKP3089C035, run by SK Life Science. Who may not be able to join: - You left or stopped participating in the previous study (YKP3089C035) early for any reason. - There have been significant changes to your...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06593951 · Boston Children's Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2029
🇺🇸 US

Who might be able to join this trial: - People who have received a molecular (genetic) diagnosis of EPM1-related disease (a rare inherited condition also known as Unverricht-Lundborg disease) - People who have access to internet-based communication tools, including video calls - People who have a permanent home address...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06598189 · Felicia Chu Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇺🇸 US

Who might be able to join this trial: - People aged 18 or older. - People who have been admitted to the UMass Memorial Epilepsy Monitoring Unit for long-term video-EEG monitoring as part of their regular epilepsy care, for either focal or generalised epilepsy. - People who are willing to wear a small wearable device du...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06598449 · University of Colorado, Denver Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - You are between 12 and 23 months old. - You have a change (mutation) in the SCN1A gene that is known or suspected to cause problems, or you have been diagnosed with Dravet syndrome, and you have had at least one prolonged seizure. - You have tried at least one seizure medica...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06608966 · Children's Hospital Medical Center, Cincinnati Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 October 2028
🇺🇸 US

**Who might be able to join this trial:** - The young person must be between 13 and 17 years old at the time of joining. - The young person must live at home with their main caregiver and be enrolled in school (not counting summer breaks). - The young person must have a confirmed epilepsy diagnosis, with seizures that...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06609889 · Berge Minassian Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 October 2027
🇺🇸 US

**Who might be able to join this trial:** - You must be willing and able to sign a consent form (and an assent form if required for your age) and follow all study requirements. - You must be between 10 and 18 years old (inclusive) at the time of signing the consent form. - Female participants must not be pregnant or b...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06617845 · Mayo Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2027
🇺🇸 US

Who might be able to join this trial: - You have had a brain stimulation device surgically implanted that targets a specific area of the brain called the anterior nucleus of the thalamus, as part of your standard treatment at Mayo Clinic. Who may not be able to join: - You are not expected to have regular follow-up ap...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06623994 · Indiana University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2028
Kenya

Who might be able to join this trial: - People aged 12 years or older - People who live in Busia or Trans Nzoia County - People who have been screened for possible epilepsy and had that diagnosis confirmed by an epilepsy-trained professional working with the BEACON project, or by a physician - People who have a diagnos...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06625112 · European STXBP1 Consortium Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 October 2029
🇧🇪 BE

"Who might be able to join this trial: - You have a genetic change in the STXBP1 gene that has been identified as likely causing disease, based on recognised medical genetics guidelines (ACMG criteria); or you have a larger change in your DNA that includes the STXBP1 gene, where that gene is thought to be responsible (...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06661759 · National Taiwan University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇹🇼 TW

Who might be able to join this trial: - Children between 1.5 and 9 years old who have a confirmed diagnosis of epilepsy. - Children whose parents have enough Chinese language skills to fully understand the trial and fill in questionnaires. Who may not be able to join: - Children who are confined to bed and unable to m...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06663969 · Xuanwu Hospital, Beijing Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2025
🇨🇳 CN

Who might be able to join this trial: - People who have been clinically diagnosed with epilepsy that has not responded to medication (drug-resistant epilepsy) - People who do not have any serious diseases affecting major body systems - People who have had stereotactic electrodes (specialised monitoring wires) surgicall...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06667232 · Xuanwu Hospital, Beijing Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 25 December 2025
🇨🇳 CN

Who might be able to join this trial: - You have epilepsy that has not been controlled by medication (drug-resistant epilepsy) and it starts in one specific area of the brain (focal epilepsy) - Your doctors have recommended a specific brain monitoring procedure called SEEG (where small electrodes are placed in the brai...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06668519 · Children's Hospital of Fudan University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2027
🇨🇳 CN

Who might be able to join this trial: - Be between 1 month and 18 years old - Have been diagnosed with epilepsy - Have been diagnosed with a brain tumor - Have been diagnosed with a blood vessel condition affecting the brain (such as a stroke or similar condition) - Have been diagnosed with autism - Have been diagnosed...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06673849 · Riphah International University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 2 December 2024
🇵🇰 PK

Who might be able to join this trial: - Children who have been diagnosed with spastic diplegic cerebral palsy (a type of cerebral palsy affecting muscle stiffness mainly in the legs) and are between 6 and 12 years old - Both boys and girls are welcome to apply - Children who have a mild level of muscle stiffness, rated...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06695767 · The University of Texas Health Science Center, Houston Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 6 February 2025
🇺🇸 US

Who might be able to join this trial: - People who are veterans and speak English - People who have home internet access - People who use a computer or tablet at least once a week and are comfortable doing so - People who do not currently have symptoms from their long-term health condition(s) - People who have a mobile...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06700356 · Mayo Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2026
🇺🇸 US

Who might be able to join this trial: - People who are 18 years of age or older. - People who have already had a specific type of brain stimulation device (called a Medtronic Percept™ DBS system) surgically placed to help manage epilepsy, and that device is able to record brain activity. - People who, or whose legally...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06700811 · Heather Olson Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 November 2027
🇺🇸 US

**Who might be able to join this trial:** - The patient's medical team is already planning to start them on a ketogenic (high-fat, low-carb) diet to help treat their epilepsy - The patient's medical team agrees that the specific formula used in this study (KetoVie) is appropriate for them - The patient is male or fema...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06701084 · Boston Children's Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2029
🇺🇸 US

Who might be able to join this trial: - The infant had their first seizure before 12 months of age - The infant is being enrolled within 6 weeks of the hospital visit related to their seizures - The infant is a patient at Boston Children's Hospital - A parent or caregiver who is the legal guardian of an eligible infant...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06708143 · Xuanwu Hospital, Beijing Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 November 2028
🇨🇳 CN

Who might be able to join this trial: - You are between 6 and 60 years old. - A doctor has determined that your epilepsy does not respond well to medication (also called drug-resistant epilepsy). - You have disabling seizures at least 2 times per month or more. - You (and/or your guardian) are willing and able to sign...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06716801 · Aziende Chimiche Riunite Angelini Francesco S.p.A Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2027
🇫🇷 FR

**Who might be able to join this trial:** - People aged 18 or older when they started taking the medication cenobamate. - People who have been diagnosed with epilepsy that causes focal-onset seizures (seizures that start in one part of the brain), whether or not those seizures spread further. - People who are still in...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06719791 · Xuanwu Hospital, Beijing Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 December 2027
🇨🇳 CN

Who might be able to join this trial: - People aged between 18 and 60 years old. - People who have been diagnosed with focal seizures (seizures starting in one part of the brain), or focal seizures that spread to affect the whole brain, according to specific 2017 international diagnostic guidelines. - People diagnosed...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT06720922 · Beijing Tiantan Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇨🇳 CN

Who might be able to join this trial: - People between 18 and 65 years of age. - People diagnosed with mesial temporal lobe epilepsy that has not responded to medication (sometimes called drug-resistant epilepsy). - People who experience seizures at least once per month. - People who have been approved to participate (...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06736002 · Chin-Wei Huang Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇹🇼 TW

Who might be able to join this trial: - You are 20 years old or older - You have been diagnosed with refractory epilepsy, meaning your seizures have not been well controlled even after trying more than two different epilepsy medications at their proper doses - Brain scans from the past three years show no signs of new...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06769659 · NeuroPro Therapeutics, Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 August 2026
🇺🇸 US

**Who might be able to join this trial:** - People aged 16 to 75 years at the time of giving consent - People who have been diagnosed with genetic generalised epilepsy that includes absence seizures, based on established international classification guidelines - People whose brain activity scan (EEG) shows a specific...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06772194 · National Taiwan University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2028
🇹🇼 TW

**Who might be able to join this trial:** - You have had a stroke confirmed by a brain scan (either a type caused by a blocked blood vessel, confirmed by MRI, or a type caused by bleeding in the brain, confirmed by CT or MRI) - You are 18 years old or older - Before your stroke, you were mostly independent in daily lif...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06778772 · IRCCS National Neurological Institute "C. Mondino" Foundation Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2025
🇮🇹 IT

Who might be able to join this trial: - People who are 17 or 18 years old. - People who have been diagnosed with epilepsy (either focal or generalised), regardless of the cause or whether they also have other neurological, psychiatric, or physical health conditions. - People whose care guidelines indicate that ongoing...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06780501 · University of Plymouth Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 May 2025
🇬🇧 GB

**Who might be able to join this trial:** This trial has two parts: a **de-identified database** (using existing medical records) and a **research register** (involving direct participation). Each part has its own criteria. **De-identified database — people who may be included:** - People who have a formal diagnosis...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06782074 · IRCCS National Neurological Institute "C. Mondino" Foundation Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 January 2025
🇮🇹 IT

Who might be able to join this trial: - People who are between 11 and 18 years old - People who have been diagnosed with idiopathic generalized epilepsy (a type of epilepsy with no known structural cause in the brain) Who may not be able to join: - People who are younger than 11 years old or older than 18 years old -...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06792383 · Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇮🇹 IT

Who might be able to join this trial: - You must be 18 years old or older at the time of joining the study. - You have been diagnosed with a type of epilepsy that has not responded well to medication (called drug-resistant focal epilepsy) and have been seen at the institute for at least 6 months. - Your epilepsy has be...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06792396 · East Suffolk and North Essex NHS Foundation Trust Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2025
🇬🇧 GB

**Who might be able to join this trial:** - Children and young people up to 16 years old who were treated for a specific sleep-related brain activity condition (called electrical status epilepticus in sleep, or a related condition affecting brain development) by doctors at East Suffolk and North Essex NHS Foundation Tr...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06794606 · Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2041
🇮🇹 IT

**Who might be able to join this trial:** - Adults who have focal epilepsy (seizures that start in one part of the brain) with a long history of seizures that have not been controlled despite trying anti-seizure medications, whether taking one or multiple medications, and where a known cause has been found on brain sca...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06798896 · Supernus Pharmaceuticals, Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 August 2027
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with focal epilepsy that has not responded well to treatment, as confirmed by a specialist epilepsy review board. - You have tried at least 2 different seizure medications at appropriate doses but have not been able to stay seizure-free on them. - You...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06813612 · IRCCS National Neurological Institute "C. Mondino" Foundation Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2025
🇮🇹 IT

Who might be able to join this trial: - Children between 6 and 10 years old, of any sex - Children who have been diagnosed with one of these specific types of epilepsy: childhood self-limiting focal epilepsy (SeLFE), childhood absence epilepsy (CAE), self-limiting centrotemporal paroxysmal epilepsy (SeLECTS), self-limi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06814665 · Haukeland University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 24 January 2027
🇳🇴 NO

**Who might be able to join this trial:** - You have had one or more events in your life that are strongly suspected to be epileptic seizures (including seizures caused by fever), and these have never been assessed by a neurologist or pediatrician before. - You have had events suspected to be epileptic seizures that a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06819670 · University of California, Los Angeles Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 28 February 2028
🇺🇸 US

Who might be able to join this trial: - The child is between 2 and 18 months old (inclusive) - The child has been diagnosed with infantile spasms syndrome and brain wave testing (EEG) has confirmed that their spasms fully responded to standard treatments (such as prednisolone, ACTH, and/or vigabatrin) Who may not be a...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06836687 · University Hospital Marburg Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2038
🇩🇪 DE

Who might be able to join this trial: - You must be at least 18 years old - You must have had your first ever epileptic seizure - You must be able to read and understand the study information provided to you - You must be willing and able to give written agreement to take part in the study Who may not be able to join:...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06863350 · Sichuan University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 60 years old, of any gender - People who have been diagnosed with epilepsy according to specific international diagnostic guidelines (ILAE 2014 criteria) - People whose epilepsy has not been controlled by at least two different seizure medications (used alo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06865820 · Emory University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 December 2026
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 years or older - People who have been diagnosed with epilepsy (based on what the person reports themselves) - People who are able to speak English - People who have access to a phone or computer Who may not be able to join: - People who are not able to cognitively...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06872125 · Stoke Therapeutics, Inc Phase 3 · 7 countries Recruiting
Recruiting Phase 3 Est. completion 1 March 2027
🇫🇷 FR🇩🇪 DE🇮🇹 IT🇯🇵 JP🇪🇸 ES🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - Children aged 2 years old up to (but not including) 18 years old may be considered. - Children with a diagnosis of Dravet Syndrome (DS), confirmed by a specialist epilepsy group, where seizures began before 13 months of age and no other cause for the condition has been found...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06883981 · University of Utah Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2027
🇺🇸 US

Who might be able to join this trial: - People who are 18 years of age or older - People with healthy cognitive function or only minor cognitive impairment Who may not be able to join: - People who are younger than 18 years of age - People with more than minor cognitive impairment Important: Always verify eligibility...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06892457 · Insel Gruppe AG, University Hospital Bern Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2029
🇨🇭 CH

Who might be able to join this trial: - Adults aged 18 or older who have epilepsy and have been prescribed an anti-seizure medication by their doctor for medical reasons - People who are willing and able to provide written consent to participate Who may not be able to join: - People who have any electrical implants in...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06904079 · Shanghai Mental Health Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are registered in the Shanghai Mental Health Information Management System - You have been diagnosed with one of six specific serious mental health conditions: schizophrenia, schizoaffective disorder, paranoid psychosis, bipolar disorder, a mental disorder related to epil...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06915649 · University Hospital, Montpellier Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2025
🇫🇷 FR

Who might be able to join this trial: - You have previously had a specific brain surgery called an Amygdalo-Hippocampectomy, performed using the exact surgical method described by this study's researchers. Who may not be able to join: - You did not have this exact surgical procedure (even if you had a similar but diff...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06922175 · Aziende Chimiche Riunite Angelini Francesco S.p.A Not Applicable · 5 countries Recruiting
Recruiting Not Applicable Est. completion 30 December 2025
🇩🇪 DE🇳🇱 NL🇪🇸 ES🇨🇭 CH🇬🇧 GB

**Who might be able to join this trial:** - People of any background, male or female, aged 18 or older at the time they started cenobamate - People diagnosed with epilepsy who have focal-onset seizures that were not controlled by 2 to 5 previous anti-seizure medications, and who then started treatment with cenobamate -...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06924086 · University College, London Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 January 2028
🇬🇧 GB

**Who might be able to join this trial:** - Children who are between 5 and 14 years old at the time of consent - Children who have been diagnosed with Lennox-Gastaut Syndrome (LGS), confirmed by a specific abnormal brain wave pattern seen on a brainwave test (EEG) at least six months before the study starts - Children...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06934356 · Yale University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2030
🇺🇸 US

Who might be able to join this trial: **For healthy adults (age 18 and up):** - You have normal vision, even if you need contact lenses or glasses to see well (soft contact lenses only) - You have normal hearing and do not need a hearing aid **For epilepsy patients who have thalamic electrodes (age 13 and up):** - Yo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06967012 · Affiliated Hospital of Nantong University Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 31 July 2027
🇨🇳 CN

Who might be able to join this trial: - The patient and/or their legal guardian has agreed to take part and has signed a consent form. - Children aged 1 to 14 years old, of any gender. - People who have been diagnosed with a specific type of epilepsy involving focal seizures (seizures that start in one part of the brai...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06967727 · Boston Children's Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2030
🇺🇸 US

**Who might be able to join this trial:** - People who have been found to have at least one harmful or likely harmful change (variant) in one of the specific genes linked to epilepsy and movement disorder conditions. The genes of interest include a long list such as CDKL5, SCN1A, STXBP1, KCNQ2, MECP2, GRIN2B, and many...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06974305 · Massachusetts General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older - *(For people with epilepsy only)* You have been diagnosed with epilepsy and have had an abnormal EEG (a brain wave test) recorded between seizures **Who may not be able to join:** - You have a medical reason why you cannot have a PET scan,...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06975800 · Trustees of Dartmouth College Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 February 2027
🇺🇸 US

Who might be able to join this trial: - You must be between 18 and 65 years old. - You must have been diagnosed with epilepsy that has not responded well to treatment, and you are already scheduled to have brain activity monitoring (electrodes placed on the brain) for your regular medical care. - If you have a legal gu...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06976788 · Assistance Publique Hopitaux De Marseille Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 25 September 2026
🇫🇷 FR

Who might be able to join this trial: - People who are aged 18 or older but under 65 years old, of any sex - People who are in general good health, with no psychiatric conditions, and no infections, inflammation, tumours, blood vessel problems, degenerative conditions, or brain injuries, as confirmed by a medical exami...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06978842 · Dux Healthcare Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2026
🇮🇱 IL

**Who might be able to join this trial:** - People aged 12 years or older. - People who have been diagnosed with epilepsy confirmed by an EEG (a brain activity test), with at least one seizure recorded during that EEG monitoring by a trained specialist. - People who have had seizures ranging from once a day to twice ov...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07010445 · Niguarda Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2026
🇮🇹 IT

Who might be able to join this trial: - People who are between 3 and 50 years old - People who have been diagnosed with epilepsy, either at the time symptoms first began or as a drug-resistant form of the condition - People who can ensure that either the patient themselves or a caregiver will participate throughout the...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07012148 · Mayo Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have epilepsy involving the temporal lobe (a specific part of the brain) and have had video-EEG brain monitoring done within the past 3 years. - People whose seizures are "focal" (starting in one area of the brain), including seizures that cause loss of awareness...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07013331 · Hospices Civils de Lyon Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 4 January 2028
🇫🇷 FR

Who might be able to join this trial: **Group 1 – People with Dravet Syndrome** - Adults aged 18 to 59 years old with a diagnosis of Dravet syndrome, confirmed through medical history, seizure type, brain wave testing (EEG), and genetic testing - There is no requirement related to how often seizures occur - The person...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07014592 · University of Michigan Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2028
🇺🇸 US

Who might be able to join this trial: - People who have epilepsy that has not been controlled by medication and have been recommended by their doctors to have brain surgery to remove the area causing seizures - People who are able and willing to give their formal agreement to take part in the study Who may not be able...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07019922 · Praxis Precision Medicines Phase 3 · 4 countries Recruiting
Recruiting Phase 3 Est. completion 1 June 2026
🇧🇷 BR🇩🇪 DE🇮🇹 IT🇺🇸 US

Who might be able to join this trial: - People who have had a specific type of genetic change in the SCN2A gene (called a "Gain of Function" variant), confirmed by genetic testing. - People whose seizures started before they were 3 months old. - People who have had 4 or more seizures involving physical movement (such a...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07026591 · Fondation Ophtalmologique Adolphe de Rothschild Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2027
🇫🇷 FR

Who might be able to join this trial: - People who are between 18 and 65 years old - People who hold a category B driving licence - People who drive at least once a month - People who do not have a medical condition that prevents them from driving, except for epilepsy (people with epilepsy may still be eligible) - Peop...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07041619 · Semmelweis University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇭🇺 HU

**Who might be able to join this trial:** - You are between 18 and 65 years old - You have epilepsy that has not responded well to medications, and after thorough testing (including brain scans and monitoring of your brain's electrical activity), a specialist team has decided that surgery to remove part of the brain is...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07046676 · The First Affiliated Hospital of University of South China Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 30 December 2025
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with epilepsy (either as a primary condition or as a result of another condition), and whose medical records are complete - People who have been regularly taking a medication called valproic acid sodium for at least 5 days, long enough for the medic...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07051629 · Suninflam Inc Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 15 January 2027
🇺🇸 US

**Who might be able to join this trial:** **For healthy volunteers (early stages of the trial):** - Adults aged 18 to 55 years old at the time of signing the consent form - People who are in good general health, as confirmed by the study doctor based on medical history and health checks - People who weigh at least 50...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07064421 · Guangzhou Women and Children's Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇨🇳 CN

Who might be able to join this trial: - Children and young people between 3 and 18 years old - People who have been diagnosed with refractory epilepsy (a form of epilepsy that has not responded well to treatment) - People who are able to stay still and cooperate during a brain scanning procedure called magnetoencephalo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07072624 · All India Institute of Medical Sciences, Jodhpur Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 15 March 2027
🇮🇳 IN

Who might be able to join this trial: - People who have had a severe head injury from a blunt force (such as a fall or car accident) and have a low level of consciousness, measured by a standard scale called the Glasgow Coma Scale (GCS), with a score below 10. - People who have had a head injury with a GCS score above...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07075380 · Fondation Ophtalmologique Adolphe de Rothschild Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2027
🇫🇷 FR

Who might be able to join this trial: - People who are 18 years old or older - People who have epilepsy Who may not be able to join: - People who have not completed a follow-up questionnaire at the 6-month mark after joining the trial Important: Always verify eligibility with the trial site directly before applying.

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07085598 · Bangladesh Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2025
Bangladesh

**Who might be able to join this trial:** - You have been diagnosed with epilepsy by a neurologist, based on having had at least two seizures (that were not triggered by a specific cause) more than 24 hours apart - Your blood test shows a low vitamin D level (below 30 ng/ml) - You are a male between 20 and 40 years old...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07087821 · NYU Langone Health Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 29 September 2027
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 or older - People who speak English (for both the UPLIFT and PACES parts of the trial) or Spanish (for the UPLIFT part only) - People who have been diagnosed with epilepsy for at least one year - People who are able to understand and agree to the study's consent pr...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07088835 · Icahn School of Medicine at Mount Sinai Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇺🇸 US

**For Healthy Participants** Who might be able to join this trial: - You are between 18 and 70 years old - You have no history of seizures or seizure-like episodes (based on your own knowledge of your health) - Your vital signs, temperature, and blood pressure are within normal ranges - You are able to read and write...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07095842 · Sohag University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 July 2026
🇪🇬 EG

Who might be able to join this trial: - The patient must be between 2 and 16 years old. - The patient must have already been diagnosed with epilepsy for at least 1 year. - The patient must have had at least one episode of prolonged, uncontrolled seizures (called convulsive status epilepticus) in the past 12 months. Wh...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07095933 · Xuanwu Hospital, Beijing Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 60 years old (inclusive), of any sex. - People who have been diagnosed with epilepsy involving focal seizures or focal seizures that spread to affect the whole body, as defined by the 2017 international epilepsy classification guidelines. - People who have...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT07096414 · Bangladesh Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2025
Bangladesh

**Who might be able to join this trial:** - You are a male who has been diagnosed with epilepsy by a neurologist, based on having had at least two seizures (that were not triggered by a specific cause) more than 24 hours apart - Your vitamin D level is low (below 30 ng/ml, as measured by a blood test) - Your Body Mass...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07102524 · TESS Research Foundation Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2030
🇺🇸 US

**Who might be able to join this trial:** - Children aged 2 to 9 years, or 10 to 20 years old at the time of screening - People with a confirmed diagnosis of SLC13A5 citrate transporter disorder, proven through genetic testing at an approved laboratory, showing specific inherited changes in the SLC13A5 gene - People w...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07110337 · Epiminder America, Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2027
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with focal epilepsy, generalised epilepsy, or both. - People whose epilepsy has not been controlled by medication (sometimes called drug-resistant epilepsy). - People who have had at least an average of one seizure per month over the past three mont...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07110454 · Epiminder America, Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2029
🇺🇸 US

**Who might be able to join this trial:** - You must have already taken part in the DETECT study and met all of its requirements to join that study - You must have received a small implanted device called the "Minder device" as part of the DETECT study - You must have finished the DETECT study, either because an import...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07116330 · Sahlgrenska University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇸🇪 SE

**Who might be able to join this trial:** **For the clinical part of the study:** - You are 50 years old or older and are being assessed for the first time for seizures or epilepsy that started after age 50, with no obvious cause identified yet - You are having your risk factors for blood vessel problems checked as pa...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07116421 · Vanderbilt University Medical Center Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 8 May 2027
🇺🇸 US

Who might be able to join this trial: - People aged 18 or older who have epilepsy - People admitted as inpatients to the Epilepsy Monitoring Unit (EMU) at Vanderbilt University Medical Center - People having their brain activity monitored through EEG (a test that records electrical signals in the brain) for at least 48...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT07141329 · Supernus Pharmaceuticals, Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2027
🇺🇸 US

Who might be able to join this trial: - People who have already completed the related SPN-817 double-blind study. - People who have been taking a steady dose of at least one but no more than four anti-seizure medications throughout the previous study. Who may not be able to join: - People who experience non-epileptic...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07145489 · Beth Israel Deaconess Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 25 September 2026
🇺🇸 US

Who might be able to join this trial: - People who have epilepsy that has not been controlled by medication - People who are 18 years of age or older - People who experience at least 2 seizures per month on average - People who have kept a detailed seizure diary for at least 3 months Who may not be able to join: - Peo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07193277 · First Affiliated Hospital of Wenzhou Medical University Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 31 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are between 60 and 85 years old (inclusive) - You have been diagnosed with a type of epilepsy called "focal epilepsy" (where seizures start in one part of the brain) for at least 2 years, based on current medical standards - You have been taking the same epilepsy medicati...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07219407 · Rapport Therapeutics Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 3 February 2028
🇺🇸 US

**Who might be able to join this trial:** - You must have already completed the related earlier study (called RAP-219-FOS-201) and tolerated the treatment well, as judged by the study doctor. - You have been diagnosed with focal epilepsy that has not responded well to treatment (sometimes called "refractory" epilepsy)....

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07224191 · NYU Langone Health Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 8 October 2028
🇺🇸 US

**Who might be able to join this trial:** *All participants must meet these criteria:* - You are between 18 and 70 years old - You are able to understand and agree to participate in the study (give informed consent) *For one part of the study (Aim 1) — people with epilepsy having surgery:* - You have had electrodes p...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07227857 · Institut de Recherches Internationales Servier Phase 2 · 5 countries Recruiting
Recruiting Phase 2 Est. completion 15 April 2028
🇫🇷 FR🇮🇹 IT🇯🇵 JP🇪🇸 ES🇺🇸 US

**Who might be able to join this trial:** - Children aged 2 to 12 years old (at the time of screening) who have been diagnosed with a specific type of severe epilepsy called Developmental Epileptic Encephalopathy (DEE), caused by a confirmed fault in a gene called KCNT1, verified through central genetic testing. - Chil...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07234695 · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2027
🇪🇸 ES

**Who might be able to join this trial:** - People who have been diagnosed with Down Syndrome, either confirmed by a chromosome test or by typical physical characteristics associated with the condition. - People who are over 40 years old at the time of their initial screening assessment. - People who have been diagnos...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07239115 · Beijing Tiantan Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 January 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are scheduled to have brain surgery (a craniotomy) to remove a tumor located in the upper part of the brain. - Scans (such as an MRI) have confirmed you have a tumor in the upper part of the brain (not in the lower back part of the brain, the brainstem, or a widespread ty...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07244328 · Second Affiliated Hospital, School of Medicine, Zhejiang University Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 30 November 2028
🇨🇳 CN

**Who might be able to join this trial:** - Adults aged 18 to 75 years (male or female) - People who have been diagnosed with a specific type of epilepsy affecting one side of a deep brain region called the mesial temporal lobe - People whose seizures have not been adequately controlled after trying at least two diffe...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT07251673 · Assistance Publique - Hôpitaux de Paris Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2030
🇫🇷 FR

**Who might be able to join this trial:** - The patient, or their legal guardian, is able to give formal consent to take part in the study. - The patient, or their legal guardian, is considered by the study team to be able to follow the study requirements. - The patient is between 6 months and 21 years of age at the t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07253701 · Karolinska Institutet Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2028
🇸🇪 SE

Who might be able to join this trial: - People aged 2 to 79 years who have recently been diagnosed with epilepsy and have not yet started any seizure medication (patient group) - People aged 2 to 79 years without epilepsy who are joining as a comparison group (control group) Who may not be able to join: - People in th...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07288788 · Sohag University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 September 2025
🇪🇬 EG

Who might be able to join this trial: - Children between 1 month and 15 years of age may be considered for this trial. - Both boys and girls are included. - Children diagnosed with idiopathic epilepsy (epilepsy with no known underlying cause) may be eligible. Who may not be able to join: - Children younger than 1 mont...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07363603 · Pirogov Russian National Research Medical University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇷🇺 RU

**Who might be able to join this trial:** - A parent or legal guardian must provide written consent before any study activities begin, and the child must also give their agreement to participate where appropriate for their age and understanding. - Children who are aged 1 year old up to (but not including) 14 years old...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07377032 · Meyer Children's Hospital IRCCS Phase 3 · 3 countries Recruiting
Recruiting Phase 3 Est. completion 1 June 2028
🇫🇷 FR🇮🇹 IT🇵🇱 PL

**Who might be able to join this trial:** - You or your child has been diagnosed with a GRIN-related neurodevelopmental disorder (GRIN-NDD) - You or your child has a specific type of genetic change (called a loss-of-function variant) in one of these genes: GRIN1, GRIN2A, GRIN2B, or GRIN2D - A parent, caregiver, or lega...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07399327 · Assistance Publique Hopitaux De Marseille Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 January 2029
🇫🇷 FR

**Who might be able to join this trial:** - The patient, their parents, or their legal representative has agreed to take part and signed a consent form - The patient is aged 12 or older and has focal epilepsy that has not responded to medication - The patient has already had a standard pre-surgical assessment, includin...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07403266 · Oils4Cure Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 June 2026
🇪🇸 ES

**Who might be able to join this trial:** - You are between 2 and 65 years old (inclusive), either male or female - You have been diagnosed with Tuberous Sclerosis Complex (TSC) confirmed by a specialist through clinical assessment and/or genetic testing - Your epilepsy is linked to TSC and has not been adequately con...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07413211 · Weill Medical College of Cornell University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2037
🇺🇸 US

**Who might be able to join this trial:** - You or your child has been diagnosed with a genetic condition linked to a Developmental and Epileptic Encephalopathy (DEE), confirmed by the study doctors - You or your child has a neurological condition such as epilepsy or developmental delay, confirmed by the study doctors...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07417280 · University Health Network, Toronto Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2035
🇨🇦 CA

Who might be able to join this trial: - People aged between 18 and 85 years old - People who have been diagnosed with a neurological condition, such as epilepsy, a brain tumour, or a movement disorder - People who have been diagnosed with a psychiatric condition, such as a substance use disorder - People who are receiv...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07445074 · University of Central Florida Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with epilepsy - People who are currently prescribed medicine to help control seizures - People who belong to a racial or ethnic group that has historically been underrepresented in research or healthcare, or who are on a low income (for example, tho...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07460037 · Second Affiliated Hospital, School of Medicine, Zhejiang University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 20 and 80 years old - People who are willing and able to understand and agree to the study procedures - People who do not have severe emotional or consciousness problems before the procedure that would prevent them from taking part in study tasks - *(For...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07490769 · Waad Alkathiri Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 December 2028
🇸🇦 SA

Who might be able to join this trial: - People who are 18 years of age or older - People who have been diagnosed with epilepsy that is not fully controlled, meaning they have had one or more seizures in the last 6 months that were not caused by an obvious trigger - People who are currently taking Levetiracetam as their...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07505004 · Praxis Precision Medicines Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 January 2027
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with focal onset epilepsy (a type of epilepsy where seizures start in one specific area of the brain), according to a recognised international classification system. - People who have had a brain scan (CT or MRI) in the past that ruled out a progres...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07509177 · Cynthia Kerson Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 11 August 2026
🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older - People who have a medical diagnosis of epilepsy and have had at least one seizure in the past 6 months (confirmed through medical records via a signed medical release form) - People who are willing to keep their current medication th...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07509190 · Anny Reyes Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2028
🇺🇸 US

Who might be able to join this trial: **Part 1 – Main study:** - People aged 18 or older who have been diagnosed with epilepsy, have completed a surgical evaluation at Cleveland Clinic, and have been recommended for brain surgery or a neurostimulation device implant. **Part 2a – Patient survey:** - People aged 18 or...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07531511 · UCB Biopharma SRL Not Applicable · 3 countries Recruiting
Recruiting Not Applicable Est. completion 25 May 2029
🇫🇷 FR🇪🇸 ES🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with a condition called SLC6A1-NDD, which involves a specific gene mutation, and who experience epilepsy, developmental delays, autism spectrum disorder, or intellectual disability as part of that condition. - People who are 17 years old or younger...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07531745 · Ionis Pharmaceuticals, Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2030
🇺🇸 US

Who might be able to join this trial: - The child must be between 2 and 12 years old at the time of signing up for the study. - The child must have at least one parent or caregiver who is 18 years or older, is willing to give written consent, and can attend all study appointments. - The child must have been formally di...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07563881 · Rapport Therapeutics Inc. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 July 2029
🇺🇸 US

**Who might be able to join this trial:** - You are between 18 and 75 years old - Your body weight falls within a healthy-to-obese range (BMI between 18 and 45) (confirm with trial site if unsure of your BMI) - You have been diagnosed with focal epilepsy (a type of epilepsy starting in one area of the brain) for at lea...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07580183 · University of California, Davis Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2030
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older - For certain parts of the study: You have been diagnosed with a type of epilepsy that affects one area of the brain, or you have a lesion (abnormal area) in your temporal lobe, and you are being evaluated for or have already had epilepsy sur...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07588971 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇮🇹 IT

**Who might be able to join this trial:** - You had your first seizure between the ages of 0 and 18 years, and a specialist has confirmed a diagnosis of epilepsy (meaning you had 2 or more unprovoked seizures at least 24 hours apart, or a recognised epilepsy condition). - You are already being seen and monitored at the...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07592676 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2028
🇮🇹 IT

Who might be able to join this trial: **For the prospective part of the study – Case Group (younger participants):** - People with epilepsy or epileptic syndromes, including those with mild intellectual disability (with or without other health conditions), and people diagnosed with tuberous sclerosis complex - People...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07594119 · Rapport Therapeutics Inc. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 July 2029
🇺🇸 US

**Who might be able to join this trial:** - People aged between 18 and 75 years old - People with a body weight in a healthy range (BMI between 18 and 45) - People who have been diagnosed with focal epilepsy (a type of epilepsy where seizures start in one specific area of the brain) for at least 24 months before the f...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07594158 · Ono Pharmaceutical Co., Ltd. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 March 2028
🇯🇵 JP

**Who might be able to join this trial:** - You are a Japanese male or female patient between 2 and 17 years old at the time of agreeing to join the trial - You have been diagnosed with epilepsy with a specific type of seizure (called focal onset seizures) that has not been fully controlled by medication for at least 6...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07594652 · Hugo W. Moser Research Institute at Kennedy Krieger, Inc. Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 December 2030
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with epilepsy and are currently taking medication to control seizures. - You have not had a cluster of seizures or a prolonged seizure emergency in the 30 days before joining the study. - You have also been diagnosed with ADHD that is affecting your d...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07600736 · Actio Biosciences, Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2027
🇺🇸 US

**Who might be able to join this trial:** - Be between 1 month and under 22 years of age - Have been diagnosed by a doctor with a specific type of epilepsy caused by a KCNT1 gene problem - Be experiencing an average of at least 4 noticeable seizures that involve movement per week - Be taking no more than 6 seizure medi...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07605858 · Hospices Civils de Lyon Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 June 2028
🇫🇷 FR🇺🇸 US

Who might be able to join this trial: - People aged 18 to 55 years old - People who have been diagnosed with epilepsy that originates in the temporal or frontal lobe of the brain, based on non-surgical testing - People whose epilepsy has not been adequately controlled by medication, as defined by the International Leag...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07651709 · The Fourth Affiliated Hospital of Zhejiang University School of Medici... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2035
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with focal or generalized epilepsy, as defined by the International League Against Epilepsy. - Women of childbearing age who are 18 years or older, and who are either planning a pregnancy or are in early pregnancy (up to 16 weeks along, confirme...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07656857 · Beijing Tiantan Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2028
🇨🇳 CN

Who might be able to join this trial: - People between 3 and 60 years of age. - People who have been diagnosed with drug-resistant epilepsy, meaning seizures have continued despite trying at least two different seizure medications at the right doses. - People who have been diagnosed with a type of epilepsy that starts...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07663578 · University of California, Davis Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 April 2027
🇺🇸 US

Who might be able to join this trial: - Adults between 18 and 65 years old who are having a brain monitoring procedure (where sensors are placed inside the brain) as part of an evaluation before possible epilepsy surgery - Healthy volunteers who do not have epilepsy are also eligible, for a non-invasive brain wave reco...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07675746 · Second Affiliated Hospital of Guangzhou Medical University Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 31 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - Children and teenagers aged 2 to 18 years who have been diagnosed with Dravet syndrome caused by a change (mutation) in the SCN1A gene, where seizures started before 12 months of age. - Participants must have had at least 6 seizures in the 12 weeks before joining, and at lea...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT07680842 · University of California, San Francisco Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2027
🇺🇸 US

**Who might be able to join this trial:** - People aged between 21 and 65 years old at the time of screening - People who have been diagnosed with epilepsy that has not responded well to medication, with an average of 4 or more seizures per month - People who are able to give their own consent to participate, or who ha...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07725601 · Fernando Vale Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇺🇸 US

Who might be able to join this trial: - People who have been assessed by their doctor as suitable for vagus nerve stimulator (VNS) implant surgery to help control seizures - People who are able to give informed consent themselves, or who have a legally authorised representative able to do so on their behalf Who may no...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Advocacy and support in Australia

Organisations that can offer information, support, or connection for Epilepsy. Where more than one is listed, they serve different needs or regions, so choose whichever fits your situation.

A few organisations support people with epilepsy, and which suits you may depend on where you live: Epilepsy Action Australia runs the National Epilepsy Line and national services; Epilepsy Australia is a national coalition of state associations; and the Epilepsy Foundation operates in Victoria and NSW.

This is a starting point, not medical advice or an endorsement. Contact details change; search the organisation name to find its current website.